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14th International Symposium on Thrombolysis, Thrombectomy and Acute Stroke Therapy 
 
The 14th International Symposium on Thrombolysis, Thrombectomy and Acute Stroke 
Therapy (TTST) took place in Houston, Texas on October 21st and 22nd, 2018.  TTST meetings 
began in 1990 during the initial simultaneous clinical investigations into thrombolysis taking place 
in the U.S, Europe, and Japan.  Since then, TTST has brought together invited experts on 
reperfusion therapy for acute stroke every two years, and rotates among venues in Europe, North 
America, and Asia. TTST has provided opportunities for stimulating controversial discussions on 
data from recent clinical trials, the status of ongoing studies, and priorities for future research. 
Initially focused on thrombolytic therapy, recent TTST conferences have helped lay the 
groundwork for the success of thrombectomy clinical research.   
The objective of TTST 2018 was to explore the changing landscape of acute ischemic stroke 
therapy and address current controversies in thrombolysis and thrombectomy. With the goal of 
reaching a consensus on how these therapies will evolve over the next several years, data of the 
relevant neuroscience was presented by experts of the field.  Importantly, the emphasis was not 
only on scientific advances, but also on expanding access by a focus on systems of care with global 
relevance.  Re-presentation of already-published data was discouraged. Invitees were selected to 
represent all specialties and regions involved in thrombolysis and thrombectomy.  The format was 
a series of 3-4 talks on a general topic followed by an open discussion.  Each talk was presented 
by a group of 3 experts and limited to 20 minutes.  Another group of 3-4 experts led the subsequent 
discussion aimed at encouraging frank and open debate among all attendees. This manuscript 
summarizes the proceedings of TTST 2018. 
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1. Changing demographics of stroke and impact on 
thrombolysis and thrombectomy  
 
Global incidence of stroke and projected future trends 
Dominque Cadillac, George Howard, Anthony Kim 
 
Annually, stroke is estimated to affect 15 million people worldwide, and is the third leading 
cause of disease burden.1 In low and middle income countries (LMIC), 94% of deaths from 
stroke occur in people aged <70 years in contrast to 6% in high income countries (HIC).2 
A clear understanding of disease trends around the world is important. In the latest 
systematic review by Thrift and colleagues3 it was confirmed that large geographical 
variations in stroke incidence and mortality persist, with the largest burden observed in 
Eastern European countries and China. However, data are lacking from many countries, 
making the world-wide assessment of the burden of stroke challenging.  The Global Burden 
of Disease study has partially addressed this gap by providing estimates of the stroke 
burden in almost all countries. The estimates are derived by using evidence from the 
literature and modelling techniques to estimate stroke burden in countries with limited 
epidemiological information that is overseen by an expert group from 41 countries.4,5  
Although there is evidence that stroke incidence rates have declined, and prevalence rates 
have remained similar, between 1990 and 2016 the absolute number of stroke survivors 
has almost doubled, and it is estimated that currently there are over 80 million people living 
with stroke (unpublished, Feigin 2018). Of great concern is that over 60% of people living 
with stroke are younger than 70 years. In HIC like Australia about 1 in 4 strokes now affects 
people aged 18-64 years, impacting their ability to work and their role in society.6 
However, the burden of stroke at lower ages is much larger in LMIC where stroke affects 
people at a younger age and where overall life expectancy is lower. In terms of disability 
and deaths, the greatest burden currently resides in developing countries, and the gap 
between developed and developing countries is increasing.4 Increasing life expectancy and 
population growth explain some of these trends which are compounded by a global 
epidemic of people with metabolic risk factors such as obesity, type 2 diabetes and 
hypertension,4 which are important risk factors for stroke.5  
These changes in the burden of disease from stroke are the result of demographics shifts, 
as well as health sector and non-health sector trends. Population growth, particularly in the 
developing world, as well as aging, particularly in upper income and middle-income 
countries, both contribute to the increasing absolute stroke burden expected in the coming 
years.7 Trends in population level for risk factors such as hypertension and the expected 
impact of both favorable and unfavorable trends vary across countries, with unfavorable 
trends in blood pressure and obesity in China and Brazil for instance, as compared to 
generally favorable trends in blood pressure and cholesterol in many developed countries, 
but not obesity.5 The net impact of these factors is that there is a substantial increase in the 
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relative age-standardized burden of stroke in the developing world, while many developed 
countries continue long-term trends of improvement, but a substantial increase in the 
absolute burden of stroke is expected with any potential improvements in incident events 
outweighed by demographic shifts.1  
In the US, the absolute age-adjusted mortality rate for stroke has potentially plateaued after 
decades of decline. Coupled with the continued “greying of America” where the population 
will continue to age in the coming decades, with substantial growth in the oldest of the old 
(age > 85) which will double from 5% to 10% of the population, there are accompanying 
changes in the race/ethnic distribution of the aged as well (Figure 1).6 A forecasting model 
that combines estimates of population growth, assumed stroke incidence rates by age, sex, 
and race/ethnicity, predicts substantial shifts in the distribution of stroke events over the 
next 40 years. A more than doubling of the total number of stroke events is expected, with 
nearly all of this increase in the elderly where the proportion of strokes occurring at ages 
75 and older increasing from 50% in 2010 to 61% in 2050. Projected changes will also 
have an impact on the race/ethnic distribution of stroke events with a decrease in the 
proportion of strokes that occur in whites from 75% to 56%, and an increase in Hispanics 
from 11% to 24%. These forecasts justify the need to expand capacity to treat patients with 
stroke, to refine interventions and therapies to the elderly population, and to focus on stroke 
care for minority populations in the future. We also need to ensure capacity building in 
LMIC countries to support efforts in the prevention and treatment of stroke, and overall, 
encourage routine and standardized data collection for better capturing the burden of stroke 
around the world. 
 
 Global rates of thrombolysis and thrombectomy 
Dawn Kleindorfer, Werner Hacke, Kazunori Toyoda 
 
Over the past decade, thrombolysis rates have increased particularly in a subset of patients 
arriving within 2 hours from time of symptom onset. Overall use of IV tPA in patients, 
without regarding time of arrival or contraindications for tPA administration, has remained 
similar.8 Utilization rate in centers located in urban communities has increased but rural 
areas don’t exhibit the same pattern. After the publication of pivotal RCTs, mechanical 
thrombectomy rates showed a significant increase in patients arriving up to 4.5 hours after 
symptom onset and an NIHSS > 5, with a significant 7% increase in all stroke patients, 
despite the fact that almost two-thirds of patients arrive in the late time window.9 In Europe, 
Germany reached in 2016 a thrombolysis rate of 13.5% and a thrombectomy rate of 4.5%, 
with access to mechanical thrombectomy becoming available for patients from rural areas, 
although at a lower rate. The far majority of patients are being treated in high-volume 
centers with more than 25 cases/year and more than 50% are treated in centers with over 
100 patients/year.10 Asia exhibits very low thrombolysis and thrombectomy rates when 
compared to each individual country’s population, as presented by Kazunori Toyoda, M.D 
by verbal communication. Access to thrombolysis and thrombectomy centers, along with 
patient eligibility at the time of hospital arrival may account for this trend.  
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Changing stroke demographics and characteristics as a result of preventive 
interventions and impact on thrombolysis and thrombectomy with focus on atrial 
fibrillation and LVO vs non-LVO stroke 
Phil Bath, Mitch Elkind, Hooman Kamel 
 
The concept of the “epidemiologic transition” has been used to explain the shift in the 
relative proportions of diseases that may occur in countries as they pass through different 
stages of development.11 Epidemiologists described at least five stages of transition.  In the 
first stage (pestilence and famine), nutritional deficiencies and infections dominate; in the 
world of stroke, Chagas disease could occur, for example. The second stage is 
characterized by diseases related to hypertension, such as hemorrhagic and small vessel 
stroke, and includes large parts of Asia, including China.  In the third stage (degenerative 
and man-made diseases), high fat diets, sedentary lifestyles, and cigarette smoking allow 
chronic, degenerative, and “man-made” diseases, including cardiovascular disease and 
ischemic stroke, to become more prominent, as in urban India. In the fourth stage (delayed 
degenerative disorders), there are increased efforts to prevent, diagnose, and treat these 
lifestyle-related diseases, which allows for a delay in their age of onset as well as the 
increase in degenerative diseases affecting the elderly. Western Europe and North America 
are considered to be in this fourth stage of the epidemiologic transition. At this stage, we 
might expect an increase in large vessel occlusions due to atrial fibrillation and other 
sources of cardioembolic stroke, as well as effects of large artery atherosclerosis, amyloid 
angiopathy, and vascular dementia. Finally, a fifth stage of societal upheaval and social 
regression may exist in which existing health structures break down, leading to a 
resurgence of conditions seen in the first two stages, as well as to the effects of violence 
and accidents (parts of post-Soviet Russia has been suggested as an example). Here, 
vascular neurologists and stroke physicians would encounter traumatic hemorrhages of 
many types. 
 
Empirical evidence of the epidemiologic transition in relation to stroke was well described 
in the Sino-MONICA-Beijing project.12  In this community-based surveillance study, there 
were temporal trends in stroke incidence and subtype in Beijing over only two decades of 
rapid economic development, from 1984 to 2004. Four characteristics of the 
epidemiological transition were observed: declining incidence of hemorrhagic stroke due 
to improved treatment of hypertension, reduced case fatality due to improved treatment 
after stroke, increased age of stroke onset, and an expanded proportion of ischemic heart 
disease deaths with a decreased proportion of stroke deaths in the study population.  
Additionally, an increase in the incidence of ischemic stroke was found which was felt to 
be secondary to increased atherosclerotic risk factors. Though not a particular focus of this 
analysis, it is likely that cardioembolic stroke related to the aging of the stroke population 
and the increase in ischemic heart disease in particular, and thus large vessel occlusion, 
would be part of this picture.  
 
 5 
Of course, the epidemiologic transition is not limited to the developing world, and 
disparities are reflected within nations. In the United States, racial minorities suffer 
increased stroke mortality and disability rates compared to non-Hispanic whites. African 
Americans have the highest mortality rates due to stroke and Hispanics have a higher stroke 
incidence than whites.  In the southeastern United States, within a region referred to as the 
“Stroke Belt”, stroke mortality and incidence rates are increased.  The highest rates are 
found along the coast, in Georgia and North and South Carolina, in a region nicknamed the 
“Stroke Buckle”.  Variations in race or ethnicity of people comprising the population do 
not appear to fully explain the disparities in stroke mortality and incidence that exist in the 
southeastern United States, since African-Americans in the Stroke Belt have increased 
stroke risks compared to those in other parts of the country.13 The difference may be 
attributable to socioeconomic factors limiting access to care, producing an increase in the 
prevalence of stroke risk factors.14 In an analysis of the National Health and Nutrition 
Examination Survey, moreover, there is evidence that despite improving trends in the 
burden of cardiovascular risk factors among high income individuals in the US, low income 
populations are not sharing in these favorable trends. 15 Thus, while there have been 
improvements in the control of risk factors for cardiovascular disease in the US, it remains 
unclear that all socioeconomic strata have benefited equally, and as the population grows, 
we can expect more LVO to occur.  
 
In this context, it is also important to ask if there are differences in the risk of LVO by sex 
or race/ethnicity. The two major stroke mechanisms leading to LVO are cardiac embolism 
and large-artery atherosclerosis. Although there is less atrial fibrillation (AF), the most 
common cardioembolic risk factor in women when adjusting for age,16 this issue is less 
relevant at the time of stroke presentation since women generally present with stroke at a 
later age. In support of this, there was an essentially even distribution of men and women 
in trials of mechanical thrombectomy or other acute stroke therapies.17 There are 
race/ethnicity-related differences in ischemic stroke subtypes, with Caucasians having a 
higher risk of cardioembolic stroke and Asians a higher risk of large-artery 
atherosclerosis.18 However, given the contribution of large-artery atherosclerosis and 
cardiac embolism to LVO, there appear to be no race/ethnic differences in LVO risk.19 
 
 
Discussion Panel 
Joe Broderick, Devin Brown, Nicole Gonzales, Anjail Sharrief  
 
With aging of the population and changes in racial demographics in the United States, we 
expect an increased number of strokes in Hispanics, elderly, females in the coming years 
and we need to be prepared for this. These changes raise a number of questions. Will we 
see an increase in patients with cardioembolic stroke requiring greater demand for EVT? 
Are we prepared? Do we have the interventionalists situated in the right regions? Currently 
rural areas are largely underserved. On the other hand, understanding the ‘denominator’ 
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helps to determine which patient population we are going to shift resources towards. The 
reality is that the percentage of patients eligible for EVT, while growing, is still small.  
 
On a global level, there are very limited data in lower income countries where incidence of 
stroke is increasing. For these countries, the best use of resources may be in prevention. 
We should not exclude the possibility that some countries may have resources to provide 
thrombolytic therapy and we should support these countries in establishing stroke centers; 
however, setting up endovascular labs and advanced imaging does not seem plausible and 
the public health benefit of endovascular therapy much more limited. Even in the US, 
despite the exciting advances in endovascular treatment, the biggest public health benefits 
are still in prevention. Finally, it important for us to see input from physicians in lower 
income countries to determine the type of support that it is needed. 
 
Key Points:  
 Stroke incidence forecasting models predict a more than doubling of the total 
number of stroke events, with nearly all of this increase in the elderly. The racial 
profile of stroke patients will also rapidly change in the next decade. 
 While there have been improvements in the control of risk factors for 
cardiovascular disease in the US, it remains unclear that all socioeconomic 
strata have benefited equally, and as the population grows, we can expect more 
LVO to occur. 
 At present, thrombolysis and thrombectomy rates around the world remain low 
relative to the clinical burden of stroke. This disparity raises serious questions 
as to our preparedness for the forecasted increased stroke numbers, and suggests 
a redoubling of efforts aimed at prevention. 
 
2. Thrombolysis and thrombectomy—where, when, and 
who?  
 
Existing and projected distribution of thrombolysis centers worldwide 
Jeyaraj Pandian, Pooja Khatri   
 
In the United States, the most recent analysis of the geographic distribution of thrombolysis 
centers from administrative data described access of the US population to all facilities that 
provided at least one case of IV r-tPA for acute ischemic stroke.20  The 2011 US Medicare 
Provider and Analysis Review (MEDPAR) data set was used, although it was limited by 
excluding patients younger than 65 years of age, except transplant and permanently 
disabled patients. Based on this analysis, by ground, 81% of the US population may have 
access to intravenous-capable hospitals within 60 minutes and by air, 97% may have access 
to intravenous-capable hospitals within 60 minutes. These projections may overestimate, 
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since provision of one dose of alteplase may not guarantee an appropriate level of 
thrombolysis readiness.  Similar good penetration of thrombolysis centers is likely in 
Canada, based on even older numbers from a 1998 publication using 1996 interim census 
numbers by Scott et al7 They used Geographic Information System (GIS) just like the US 
study, but identified hospitals capable of delivering IV r-tPA as those with a CT scanner 
and a neurologist and EM specialist on staff, as opposed to the actual administration of at 
least one dose of IV rtPA. 67.3%, 78.2%, and 85.3% of the total Canadian population were 
within 32, 64, and 105 kilometers, respectively, of an identified hospital. 
 
Among the South Asian countries, India and Thailand have organized stroke programs with 
thrombolysis and thrombectomy capable centers. The IV thrombolysis rates in India (1.25 
to 4.58%) and Thailand (4.78%) are growing every year. There are 75 centers in India 
currently offering mechanical thrombectomy with an overall of 1,000 procedures a year. 
In India the government has approved the use of tenecteplase, a generic biosimilar which 
is cheaper than alteplase for acute stroke treatment. Over 4,800 patients have received 
tenecteplase in the country. In Thailand, 25 hospitals offer endovascular treatment for 
stroke. In Pakistan and Srilanka, IV thrombolysis is being used but only a few centers may 
provide EVT. For South Korea, government nationwide initiated 11 Regional 
Comprehensive Stroke Center since 2008. After the initiation, door-to-needle time for the 
intravenous thrombolysis was shortened to less than 30 minutes in the CSCs and the chance 
of intraarterial thrombectomy was increased from 30% to 47% in 2016 after the initiation 
of the CSCs. However, the quality of acute stroke management including thrombolytic 
therapy has not been clearly known in the provincial area of South Korea.21  
 
Where and for whom should thrombolysis be done  
Phil Scott, Henry Ma, Didier Leys 
 
Use of thrombolytic therapy in acute ischemic stroke patients requires an initial recognition 
of stroke symptoms, confirmation of diagnosis and eligibility for therapy, proper delivery 
of thrombolytic agent, and a follow-up period post treatment. A prompt recognition of signs 
or symptoms associated with stroke in the prehospital setting is crucial in reducing delays 
to stroke identification and time from onset to hospital arrival, thus increasing the number 
of patients that may be eligible for thrombolytic therapy. Utilization of a single emergency 
number may speed healthcare access, along targeted education programs for physicians, 
hospital and EMS personnel have demonstrated utility in increasing thrombolytic treatment 
rates.  
 
Confirmation of diagnosis requires a focused history and through neurological examination 
to rule out other causes of acute neurological deficits. Minimal neuroimaging requirements 
include a noncontrast head CT, with a CT angiogram as a tool to identify patients with a 
large vessel occlusion who would benefit from mechanical thrombectomy. New emerging 
technologies such as machine learning and biomarkers may aid in the near future to 
accurately define a positive stroke. As evidence from clinical trials becomes available and 
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the experience in thrombolytic administration increases, some of the exclusion criteria are 
changing from absolute to relative, allowing more patients to benefit from medical 
management. Therefore, the physician should evaluate on an individual case basis the 
benefits and risks of thrombolysis.  
 
Delivery of thrombolytic therapy may occur in the field through mobile stroke units or in 
the emergency department/hospital. European systems of stroke care have demonstrated 
that the prehospital intravenous administration of alteplase can be accomplished effectively 
and increases the proportion of patients receiving thrombolysis within 60 minutes of onset. 
Prehospital administration of alteplase may translate into better outcomes in patients with 
pre-stroke dependency compared to in-hospital administration.22 Generalization of pre-
hospital delivery of thrombolytics faces challenges in non-densely populated regions and 
in non-resource rich communities.  
 
Expanding Thrombolytic Use Safely 
Minimal resources need to confirm eligibility for thrombolytic treatment are currently 
based on either a checklist approach identifying evidence based inclusion and exclusion 
criteria or utilizing physicians with stroke thrombolytic expertise, again, provided either at 
the bedside or remotely via telemedicine. Further minimal requirements include initial 
selection of a specific thrombolytic agent to be used (which includes cost, actual drug 
availability, physical drug stability, and physical drug delivery (availability of intravenous 
infusion pumps, etc.) which are important considerations in limited resource environments 
globally. Finally, minimal resource requirements for the management of post thrombolytic 
treated patients require cardiac and blood pressure monitoring and management capability.  
This can be implemented using, again, either a checklist approach by local post-
thrombolytic care providers or accessing physicians with thrombolytic expertise either at 
the bedside or remotely via telemedicine and includes management of treatment 
complications. 
 
Numerous points in the stroke chain of survival exist in which to improve and expand 
thrombolytic use safely. Improved prehospital systems reduce delays to stroke 
identification and treatment. Data indicate that public education to identify stroke 
symptoms and recognition of stroke as an emergency and that is sustained over time 
reduces delays. Utilization of a single emergency number (911 in the United States and 
112 in the European Union) also speeds healthcare access. Targeted education programs 
for physicians, hospital personnel and EMS personnel have demonstrated utility in 
increasing thrombolytic treatment rates. Finally, consistent utilization of prehospital 
notification by EMS personnel has been demonstrated to reduce in-hospital delays to stroke 
treatment. 
 
In communities where thrombolytics are administered only within a stroke unit, 
opportunities to expand use safely include starting treatment prior to stroke unit admission 
by providing remote neurologic expertise either in person or by telemedicine. Interactive 
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and multifaceted training programs for emergency physicians have demonstrated increased 
access to thrombolytics in the community setting. These programs frequently include an 
organized protocol for emergency evaluation. 
 
The existing paradigm of excluding patients from thrombolytic use on the basis of time has 
the potential to yield to a future paradigm where patients are excluded on the basis of 
perfusion imaging. This reflects prominent advances in the fields of neuroimaging to 
provide meaningful information on local tissue viability in stroke. If ultimately proven 
efficacious, such a shift will remove the single most common barrier to thrombolytic 
treatment–time from symptom onset. 
 
As experience with thrombolytic delivery increases and further data on thrombolytic use 
becomes available, some prior exclusion criteria are migrating from absolute to relative. 
Note should be made by the practicing clinician that the level of evidence for this migration 
frequently comes from non-randomized trials.  
 
 
Discussion Panel 
Chris Lewandowski, Wade Smith, Nerses Sanossian, Martin Ebinger   
 
The use of intravenous thrombolysis in the Emergency Department is hindered by the 
limited clinical experience and teachings of the average emergency department physician. 
About 8 percent of emergency medicine consults corresponds to acute stroke, with 1 to 2% 
being ischemic stroke. It is estimated the ED doctor treats 2 acute ischemic stroke patients 
per decade with thrombolysis. The lack of experience and the low availability of 
neurologists on site doesn’t allow for physicians in the front line to take a more active role 
in the care of stroke patients. It is thought that by simplifying the review of eligibility and 
providing support for the use of thrombolysis more physicians may feel comfortable 
delivering thrombolytics to patients. Telemedicine has proven to be an essential tool in this 
process, as well as involving nurses and advanced nurse practitioners in the stroke care.  
In addition, further development of pre-hospital triage is needed. There have been major 
advances in the prehospital evaluation and triage of stroke in the last few decades. Progress 
has been made in education of the lay public about the importance of activating Emergency 
Medical Services (EMS) as soon as stroke is suspected, prehospital stroke identification, 
and routing of stroke patients to designated acute stroke center hospitals. Areas of active 
investigation in prehospital stroke include in-ambulance therapy (i.e. neuroprotective 
agents), mobile stroke unit ambulances with imaging capabilities, and multi-tiered routing 
protocols. The goal of any prehospital system of stroke care is to deliver patients quickly 
and safely to the most appropriate hospital. 
Prehospital large vessel occlusion (LVO) triage may delay IV tPA in patients without LVO 
through longer transport times and bypass of closer hospitals, since treatment of AIS with 
IV tPA is time dependent and every 15-minute delay in IV tPA reduces the chance of 
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functional recovery.23,24 A false-positive prehospital LVO stroke triage assessment (over-
triage) may direct EMS to extend transport times by bypassing an IV tPA-capable hospital 
in favor of a more distant higher level of care, contributing to worse outcomes and may 
decrease efficiency of non-thrombectomy hospitals due to reduced case volume and 
experience,25 whereas more specialized centers may become crowded with patients not 
requiring their advanced expertise and be unable to accept transfers of complex cases as a 
result of increased volume.26  
On the other hand, stopping for IV tPA at a non-thrombectomy-capable hospital delays 
endovascular thrombectomy which, like IV tPAis highly time-dependent.17,27,28 A false- 
LVO assessment may route a patient with AIS-LVO to a hospital without endovascular 
capabilities (under-triage). For patients requiring secondary transfer, inter-hospital 
transport delays EVT by 95-109 minutes,29,30 and transfer delays of more than an hour are 
common.31 Every 4-minute faster start of thrombectomy lowers the degree of 90-day 
disability (mRS shift) for 1 of 100 treated patients.32 For dichotomous outcomes, mistriage 
is associated with an absolute 8% decrease in freedom from disability and an absolute 9% 
decrease in functional independence.33 
We need to get the right patient to the right place in the right time. EMS exists to identify 
and stabilize patients with time dependent emergencies while ensuring the right patient gets 
to the right hospital in the right amount of time. This art of triage may bypass the closest 
facility for the most appropriate facility and, when performed correctly, improves outcomes 
after trauma,34 acute myocardial infarction,35,36 and out of hospital cardiac arrest.37 Proper 
EMS triage can be the most cost-effective strategy in developing systems of care and is 
favored over creation of more specialty receiving facilities.38 Under-triage, or taking a 
patient to a lower-level of care than optimal, introduces delays due to secondary transfer. 
Emergent definitive neurosurgical care with ventriculostomy, decompressive craniectomy, 
or aneurysmal clipping or coiling for ICH39,40 and SAH41-44 is unnecessarily delayed. Over-
triage, or taking a patient to a higher level of care than required, can overwhelm highly-
specialized centers and impact the ability to accept higher-acuity transfers due to capacity, 
can starve less-specialized centers of case volume and clinical experience, and can delay 
care for patients who do not need the advanced therapies offered at the specialty center 
(e.g., prolonged time IV tPA).   
In the setting of stroke, almost all published experience with existing EMS triage tools 
focuses on identifying patients with LVO, which conflicts with the purpose of triage itself 
which is to get the right patient to the right place in the right amount of time, regardless of 
diagnosis. We need to refine prehospital assessment of stroke patients to focus not only on 
LVO but on how to best get patients the care they need to improve outcomes and increase 
disability. This may require a regional approach, but making thrombectomy available to 
the greatest numbers of individuals in the shortest time will require development of new 
prehospital tools.   
Key Points: 
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 Earlier identification of stroke syndromes, particularly in pre-hospital 
settings, is crucial to ensure the right patient is treated in the right place. 
 Minimal requirements for thrombolysis are being and should continue 
to be rethought, as treatments are moving out of specialized centers and 
closer to patients, particularly through Mobile Stroke Units. 
 As thrombolysis becomes a viable treatment options for greater 
numbers of patients through increasingly complicated imaging and 
decision-making pathways, the need for additional availability of 
Neurology expertise, or training of ED physicians, gains heightened 
relevance. Options include telemedicine, checklists, and consistent 
messaging to ED providers.  
 
 
Existing and projected distribution of thrombectomy centers worldwide 
Raul Nogueira, May Nour, Olvert Berkhemer 
 
The mismatch between lower resources and the increased stroke incidence is a devastating 
challenge that demands a timely solution. Despite the increased number of centers capable 
of carrying out mechanical thrombectomy, long travel times and delay in identification of 
patients with LVO who should be transferred to comprehensive stroke centers limit stroke 
care. In the United States, the two most prevalent certifying bodies are the Joint 
Commission and the DNV-GL. There are 194 CSCs accredited by the JC as a facility with 
NeuroInterventional coverage with a neurologist on site and a backup physician, with 
coverage for stroke neurology, neurosurgery, and neurocritical care coverage available 
24/7. 67 current CSCs accredited by the DVNGL are required to provide only 
neurointerventional coverage 24/7 and have the ability to either accommodate or transfer 
out neurosurgical emergencies. In March 16, 2018, the JC in collaboration with the 
AHA/ASA certified the first Thrombectomy-capable Stroke Center (TSC) defined as a 
facility with EVT capability 24/7, have at least 15 patients with ischemic stroke in the past 
12 months or at least 30 patients over the past 24 months, and was required to collect data 
for 13 standardized performance measures, and meet expectations of neurological expertise 
availability aligned with that of a CSC. These certifications served the goal of improving 
patient outcomes by facilitating access to care for stroke patients, so patients with a 
suspected LVO would get re-routed to the nearest CSC or TSC center rather than to a PSC.  
In Canada, thrombectomy access is evolving with a projected creation of 6 centers across 
the country. Latin America has a very limited distribution of thrombectomy centers when 
compared with the increase morbidity and mortality associated with acute stroke. In Europe 
32% of the countries have overall EVT coverage, with the rest not providing EVT due to 
high costs and lack of trained personnel and facilities. 29% of eligible EVT patients were 
treated in 2016, and around 52% of centers are available 24/7.45 
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Where should thrombectomy be done—centralized vs distributed model; what do 
the guidelines say and how do they square with reality? 
Tudor Jovin, Bernard Yan, Diogo Haussen  
 
The American Stroke Association 2018 guidelines regarding the provision of 
thrombectomy services to acute ischemic stroke clearly recognizes that patients should be 
treated at experienced thrombectomy centers with rapid access, qualified 
neurointerventionists, and comprehensive periprocedural care team.46 Evidence for other 
neurological diseases, such as subarachnoid hemorrhage and carotid endarterectomy, prove 
a worse clinical course in patients treated by lower volume operators at low-volume 
centers.47-56 This is buttressed by similar experiences in the field of coronary percutaneous 
intervention and trauma.57 Importantly, both operator and center volumes metrics are to be 
considered together, since one affects the other when evaluating for quality of care.58  The 
data on mechanical thrombectomy has accrued and uniformly point towards improved 
outcomes in patients treated in higher volume centers.59,60  
 
Significant concerns and unease were voiced by the presenters and the audience of the low 
volume (fewer than 15 thrombectomies per annum) required by the Joint Commission to 
qualify as a thrombectomy center, especially since most centers performing 
thrombectomies appear to have volume <10 thrombectomies per year (and therefore 
expected lower quality of care). The presenters also outlined different models of care 
including a decentralized model whereby high volume neurointerventionists travel to the 
spoke center to provide thrombectomy services.   
 
 
Discussion Panel 
Carlos Molina, Ed Jauch, Albert Yoo  
 
The question of who should be performing EVT, both in terms of physician qualifications 
as well as hospital qualifications, was a central question during this meeting, and one that 
pervaded nearly all the discussions of the first day. In this discussion section, the speakers 
noted that there is an ongoing debate regarding manpower needs for mechanical 
thrombectomy and more broadly for neurointerventional procedures, which include 
treatments such as aneurysm coiling and AVM embolization. However, this debate ignores 
the fact that most neurointerventionists coming out of training do not move to underserved 
communities. They move to metropolitan areas where established practices already exist. 
Healthcare systems shoulder some of the blame. Despite the presence of nearby 
comprehensive stroke centers, in the United States hospitals are incentivized to become 
comprehensive or thrombectomy-capable centers to capture EMS traffic and the higher 
reimbursements associated with thrombectomy care. As a result, neurointerventional 
practices are competing for smaller and smaller case volumes, and the debate has naturally 
shifted to focus on the better outcomes at high-volume centers as an argument to stem this 
tide.   
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Meanwhile, populations residing in rural markets are being neglected. Patients who suffer 
a large vessel stroke in these communities must be transported to the closest major city. 
Unfortunately, transport can take several hours even with air transport. Despite 
publications projecting adequate neurointerventional availability to much of the US 
population, there is a clear need to better distribute thrombectomy expertise to underserved 
areas, given the highly time sensitive nature of large vessel stroke. If there are not enough 
aneurysms or AVMs to support a full-time neurointerventionist in a rural market, then other 
interventional disciplines (peripheral radiologists or when necessary even interventional 
cardiologists) may be trained to provide thrombectomy care. Alternatively, 
neurointerventional training and certification guidelines may need to be altered to 
accommodate this shift in modern neurointerventional practice, in which the largest need 
is for acute ischemic stroke, and as such requirements mandating high numbers of 
aneurysm and AVM treatments may be outdated. In such a system, additional 
thrombectomy-capable interventionists would be credentialed to treat large vessel strokes 
in regions where there is demonstrated need. Although thrombectomy care in the rural 
setting is likely to be less optimal than at high-volume centers in major cities, it may be 
better than the alternative which is to delay treatment by hours or to have a high proportion 
of cases that do not meet treatment criteria due to a combination of late arrival and large 
infarct volume (i.e., futile transfers).61,62 The neurointerventional community along with 
other professional organizations should propose criteria for defining areas in need of local 
thrombectomy expertise and decide what constitutes adequate thrombectomy training and 
long-term quality assurance in these areas. Hybrid models including tele-
neurointerventional expertise for intra-procedural decision making may help to bridge the 
quality gap. As technology continues to advance, remote robotic intervention may also be 
possible. 
 
 Key Points: 
 At present, there is a palpable shortage of access to high quality EVT care. 
This shortage is present in developed as well as developing nations globally. 
This is an issue for both hospitals/stroke systems of care as well as physicians, 
and in particular, thrombectomy providers.  
 Alternative models of stroke systems of care have developed to improve 
patient access. These models include improved pre-hospital routing 
paradigms, improved intra-hospital transfer paradigms, and models in which 
thrombectomy providers travel to outlying hospitals. All these systems 
however remain imperfect and limited, and ultimately, increased numbers of 
thrombectomy-capable physicians and provider teams are needed. 
 There is a clear need for additional data examining outcomes data in low 
volume centers, and by low volume practitioners. The outcomes are likely to 
be poorer, but how much so? And is that decrement in outcome outweighed 
by the time delays associated with transfers?  
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Summary of new data from clinical trials of thrombolysis since ISC or ESOC 
 
WAKE UP and ECASS 4 primary results and secondary analyses 
Werner Hacke 
 
The primary results of two trials testing the efficacy of rtPA in patients with longer or 
unknown time window using advanced imaging selection were presented at ESOC 2018 in 
Gothenburg. The WAKE-UP trial was terminated early for lack of funding. It selected 
wake up stroke patients on the basis of the DWI-FLAIR Mismatch concept. Despite the 
early termination the study showed a highly significant advantage in reaching mRS 0,1 for 
rtPA in patients with a positive DWI-FLAIR mismatch (OR 1.63 95% CI 1.09-2.36, 
p=.02,).63 
 
ECASS 4 used the classic DWI-Perfusion mismatch in patients between 4.5-9h or in wake 
ups. It was also terminated prematurely because of futile recruitment because of massively 
increasing use of thrombectomy in this patient group. The OR point estimates were like 
anticipated in favor of rtPA treatment (OR 1.23 for the categorical shift, OR 1.38 for mRS 
0,1), but the confidence intervals were wide and clearly overlapped unity because of the 
small sample size.64 
 
Further ECASS 4 secondary analyses presented in Montreal (WSC 2018) indicated that 
this type of selection is more useful in known, late time window than in unknown time 
window. Using the FLAIR-DWI Mismatch paradigm in a non-predefined sub analysis of 
ECASS 4 showed also a clear trend towards better results in the DWI-FLAIR Mismatch 
cohort, but with the caveat of increased late (stroke unrelated mortality signal in the rtPA 
treated group). Again, due to the small sample size the CIs overlapped the unity line. 
 
EXTEND 
Henry Ma, Bruce Campbell, Mark Parsons, Stephen Davis, Geoffrey Donnan  
 
EXTEND is a multicenter randomized double-blind placebo- controlled trial of alteplase 
in ischemic stroke patients presenting within 4.5-9 hours from onset or those with wake-
up stroke (WUS). Selection was based on automated perfusion imaging software showing 
salvageable brain tissue. Primary outcome was excellent functional outcome (modified 
Rankin Score, mRS 0-1) adjusted for age and baseline NIHSS at 3 months.65 Other 
prespecified outcomes included independent functional outcome (mRS 0-2), early 
reperfusion, clinical improvement with NIHSS reduction of 8 points or reaching 0-1 at 24 
hours, death and symptomatic intracerebral hemorrhage (sICH). After 225 of the planned 
310 patients had been randomized the study was terminated early after the publication of 
WAKE UP study and loss of clinical equipoise.  Patients who received alteplase achieved 
significantly better functional outcomes at three months. Secondary end points including 
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reperfusion, early neurological improvement were superior in the alteplase group while 
mortality was not significantly different.  EXTEND is the first positive thrombolytic trial 
in the extended time window using automated penumbral selection software. 
 
3. Structuring Stroke Systems of Care 
 
Drip and ship—safety, what is an acceptable time delay, what imaging should be 
done and where 
Atte Meretoja, Sheryl Martin-Schild, Heinrich Audebert  
 
The drip-and-ship model of treating with thrombolytics facilitates access to time-sensitive 
proven intervention to more patients with suspected stroke.  One consequence of this model 
is that patients treated with thrombolytics are vulnerable to complications while in transit 
via ground or air ambulance. While remote guidance provides access to otherwise 
unavailable neurological expertise for decision making for ischemic stroke thrombolysis, 
the dripping sites usually have lower volume of acute strokes and may be less efficient in 
treating with thrombolytic than the hubs.  This complicates the analysis of whether there is 
advantage for patients with suspected stroke stopping at a thrombolytic capable spoke 
versus bypassing in favor of access to the hub, where definitive care can be provided, 
particularly for patients who are candidates for thrombectomy. Reducing the door in-to-
door out for sites who do not keep post-thrombolytic patients and for those patients who 
have emergent large vessel occlusion is a major opportunity for process improvement.  In 
most ischemic stroke patients, the only imaging test necessary for decision-making is the 
non-contrast head CT. In our new world of treatment for stroke due to large vessel 
occlusion, access to and appropriate utilization of endovascular resources is critical.  
Vascular and penumbral imaging may evolve, particularly when thrombolytic is given.  
The “want to know” must be balanced with the “need to know” and is most relevant for 
sites who keep post-thrombolytic patients who do not require thrombectomy for large 
vessel occlusion. Depending on hub priorities and tolerance of limitations, clinical tools 
for identifying patients with large vessel occlusion may substitute vascular imaging and 
reduce the need for repeating studies upon arrival at the hub. 
 
a) Successful networks in resource rich and poor, urban and rural regions 
Lee Schwamm, Markku Kaste, Tsong-Hai Lee  
 
Finland is presented as an example of a successful European network. After organizing 
acute stroke care and stroke unit care in Helsinki University Hospital, Dr. Kaste and the 
leadership team in Helsinki encouraged other Finnish university hospitals to follow their 
example. To ensure equal access to high-quality acute stroke care including thrombolysis 
for the entire population of Finland, the Helsinki team developed a telestroke program to 
support rural hospitals with low resources. These hospitals now have equally good results 
from thrombolysis as have been observed in Helsinki University Hospital. Through 
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telestroke, assistance to rural hospitals in recognizing thrombectomy candidates is given, 
and when appropriate, patients are transfer to the nearest university hospital applying the 
drip-and-ship method.  The ways in which other European countries have done the same 
differ by country, but high-quality stroke care is ensured over much of western Europe. 
 
In Asia, the resource-rich areas, mainly high-income countries, have sufficient support for 
acute stroke treatment networks in urban areas. However, in some rural areas where 
resources limited, there are still problems of lack of public awareness of stroke and limited 
access to mechanical thrombectomy. The establishment of stroke centers should be helpful 
in public and provider education, and the diagnosis and treatment of stroke. 
 
Key components to implementing an effective Stroke System of Care (SSOC) include the 
need to factor in the nature of the First Responders (e.g., fire/police/volunteer, BLS, ALS, 
Paramedic, Flight Nurse) and how they can bring to bear various levels of education and 
training into a more standard approach to prehospital diagnosis (Figure 2); incorporate 
EMS assets effectively, taking into account EMS ground, air, ship and Mobile Stroke Units 
as available to provide the greatest coverage without depleting critical resources from a 
community for too long; create regionalized point of entry routing plans for suspected 
stroke destination so that the region fairly allocates suspected stroke patients to a level of 
capability that fits the resources. It will be important to maintain a strong PSC network 
while developing a broader plan for rapid access to EVT at TSC and CSC facilities; 
standardize stroke alert pre-arrival notification and severity scale use so that each 
community or state becomes comfortable in the use of a single scale and can thereby 
communicate more effectively; implement a tiered accreditation or designation of stroke 
centers that includes the recommended levels of Basic, Acute Stroke Ready, Primary and 
Comprehensive; these activities should ideally be done by national organizations, since 
national organizations provide greater transparency and uniformity, and potentially better 
outcomes. These systems should encourage high levels of participation in National QI 
programs with recognition for performance to ensure that systems are based on 
infrastructure and performance.  
Discussion Panel 
George Tsvigoulis, Michael Lerario, Nate Bornstein, Claude Nguyen   
 
Traditional hub and spoke networks for acute stroke treatment were developed to balance 
resource allocation in urbanized, resource rich regions and improve access to care in rural, 
resource poor regions.  However, as the need for thrombectomy services expands and 
technology is increasingly used to improve triaging decisions, newer stroke systems have 
developed and compete with hub and spoke networks utilizing drip and ship protocols in 
both resource rich and poor regions.   
 
Examples of stroke system innovations disrupting current drip and ship networks include 
those where field triage is performed to bypass suspected large vessel occlusion (LVO) 
patients directly to a hospital with thrombectomy services.  Field triage can be 
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accomplished through standard emergency medical services staffing,66 through 
telehealth,67 or through the use of mobile applications68 and may improve time efficiency 
and outcomes in time-sensitive stroke care.  Mobile stroke units offer comparable services 
to primary stroke centers and can assist in the triaging of suspected LVO patients directly 
to endovascular centers without delaying thrombolysis times.69 Prospective studies are 
underway to ascertain if these newer methods of stroke triaging will continue to supplement 
or even replace drip and ship networks. 
 
Drip and ship networks alone cannot optimize resource utilization since false positive 
screens may occur up to 40-50% of the time if only clinical scores are used for LVO 
assessment,70 and recanalization of an identified LVO may occur in 10-20% of patients 
during transport to the hub facility as a result of intravenous thrombolysis.71,72 These 
factors generate confusion as to whether vessel imaging should occur at the hub or spoke 
facility and may result in overtriage of stoke patients to endovascular centers, when a 
primary stroke center may have been sufficient. Overtriage to advanced stroke centers 
could theoretically burden hub hospitals with unnecessary transfers and decrease volumes 
at spoke centers where competencies may be more difficult to maintain if patient numbers 
diminish.   
 
 Key Points: 
 Stroke systems of care will need to be restructured to improve patient access 
to EVT. Key elements include reducing door-in-door-out times, determining 
whether clinical tools for evaluating for LVO may substitute for imaging, and 
improving access to subspecialty care with technology including telemedicine 
and mobile stroke units. 
 Standardization of pre-hospital notifications and pre-hospital routing changes 
to avoid overtriage to comprehensive centers will be important. 
 
 
 
Who is carrying out thrombolysis and who should do it in the future? 
Andrew Demchuk, Steve Levine, Elizabeth Jones   
  
Thrombolysis is carried out in hospitals, emergency departments and in the field with the 
help of mobile stroke units. IV tPA can be administered by non-vascular and vascular 
neurologists, emergency medicine physicians, residents and fellows in the training 
programs, physician assistants and advanced nurse practitioners. Telemedicine from the 
MSU has allowed for more patients, especially in the rural networks, to get access to 
thrombolysis and for neurology expertise to become readily available for decision-making. 
In controlled trials, telemedicine in stroke consultations within an organized system of care 
have demonstrated improved and safe IV tPA use and better patient outcomes than without 
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telemedicine coverage. Many networks, including hub and spokes, have developed 
telestroke coverage for their patients, including some rural networks.  
 
In the near future, proper support for health providers from vascular neurologists should 
allow expanding and improvement of stroke patient care, empowering the autonomy of 
providers in the decision-making of thrombolysis. Guidance by a vascular neurologist, 
either on the field or through telemedicine, will lead to more patients getting the proper 
treatment, at the right time and the right place.    
 
Who is carrying out thrombectomy and who should do it in the future? 
Arthur Day, Marc Ribo, Reza Jahan 
 
Almost all stroke programs across the United States are now led by a neurologically-trained 
subspecialist practitioners being either neuroradiologists, neurologists, or neurosurgeons 
who are doing intracranial thrombectomy, with only a small number of non-neurologic 
subspecialists with catheter skills due to their training and routine practice that are now 
venturing into the intracranial circuit, which may include vascular surgeons, cardiologists 
and interventional radiologists. (Table 1) The existing dichotomy on who should be doing 
thrombectomy in the future has on one side the scenario where more subspecialties should 
be able to deliver intracranial thrombectomy as the number of practitioners does not meet 
the needs of stroke care, while on the other hand, it is not a matter of available providers 
but a lack of an equally distributed and available expertise in small or rural communities.  
 
The reason of a more restricted delivery of thrombectomy between providers is the 
complex access to the delicate intracranial vasculature which has a higher risk of 
perforation or distal embolization than the extracranial circulation, the need of a more 
comprehensive knowledge of the anatomical variants and functional anatomy of the 
collateral circulation, as well as the awareness of the physiology and pathophysiology of 
the disease which is entirely different from other organ systems suffering from infarction. 
This organ-specific expertise is what limits, to say, a neurosurgeon or radiologist from 
performing an arteriography and stenting in the management of a myocardial infarction. 
Future safe practice of intracranial thrombectomy requires a practitioner with highly skilled 
with intracranial catheter-based vascular techniques, with a firm knowledge base of the 
anatomy, pathophysiology, and treatment alternatives of the various cerebrovascular 
conditions that may arise during the evolution of a thrombotic stroke. (Figure 2) Further 
research will be needed to ascertain the number of trained physicians to meet the demands 
of stroke intervention, distribution of these physicians across the nation and better 
understanding of access of populations to stroke centers to help on planning regional stroke 
programs. 
 
Current guidelines for training for thrombolysis and thrombectomy; 
appropriateness of current guidelines 
Sunil Sheth, Don Heck, Diogo Hausen, Jim Grotta  
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Performance and training standards set by a multi-society consensus (CAST) for neuro-
interventional training demands a proper 1-year minimum training under direction of 
multiple neurointerventionists at a high-volume center. Pre-requisites to training include 
neuroscience-based residency training. A distribution of diagnostic and interventional 
procedures, covering the breadth of neuro-interventional diseases including cerebral 
aneurysms, cerebral AVMs as well as spinal diseases is required. Final certification is 
obtained following the completion of such a training program as well as a review of two 
years of subsequent practice data, to ensure high quality outcomes after training. 
 
Should the standards for stroke thrombectomy be different? On the one hand, there is a 
clear and present need to expand patient access to the therapy. This treatment is highly time 
sensitive – perhaps one of the most time sensitive in medicine – and as such delays in 
treatment such as those created by prolonged pre-hospital transports or inter-hospital 
transfers are costly. On the other hand, all the data supporting the efficacy of EVT at 
improving clinical outcomes after LVO stroke were derived from high volume hospitals 
and high volume neurointerventionalists. As such, treatment outside these specialized 
centers could be considered unproven. 
 
Would it be beneficial then to train a group of neurointerventionalists for EVT alone, and 
forgo the remainder of neurointerventional training? Insisting that all providers to treat 
stroke also be proficient in aneurysm treatments, for example, would likely be 
mathematically impossible. But would a model in which some providers perform only EVT 
be even possible, whereby one can learn to effectively perform delicate and intricate intra-
cranial thrombectomy without exposure to other cerebrovascular disorders?  
 
Ultimately, these discussions should be framed in the context of what is best for patients, 
and not along specialty or “turf” considerations. As such, this topic is one that will need to 
be addressed with data, particularly from lower volume centers and lower volume 
physician practices, which are notoriously absent from traditional data generating 
mechanisms including clinical trials and clinical registries. 
 
Discussion Panel 
Mike Frankel, Gary Spiegel, Hen Hallevi, Jonathan Zhang  
 
Since the FDA approval of tPA (Alteplase) for acute ischemic stroke in 1996 and the 
publication of consensus guidelines the acceptance by the medical community has been 
mixed. Although vascular neurologists have fully embraced the robust nature of the data 
supporting the benefit of tPA there has been reluctance to treat by general neurologists and 
emergency medicine physicians in large part due to fear of causing harm. As such, it is 
imperative that vascular neurologists work together to create more opportunities for clinical 
coverage through telestroke and education of general neurologists and emergency medicine 
physicians.  
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In the case of thrombectomy, adoption of the procedure has not been a problem. However, 
a strategy to equally distribute neurological expertise for thrombolysis and thrombectomy 
in both urban and rural areas may lead to certification of centers and physicians not fully 
competent to be involved in stroke care. Expanding certification of centers to deliver 
treatment to all population is only part of the solution, as more expertise from first 
responders and ways to reduce onset to door time play an important role in patient care. 
On the other hand, certifying non-neuroscience-based physicians, such as cardiologists or 
interventional radiologists, to perform thrombectomy requires a thorough review of 
training requirements and experience. It is clear that extracranial vessels differ enormously 
from intracranial vessels, hence a singular set of technical and cognitive expertise, as well 
as catheter-based skills and knowledge is necessary to better perform at the thrombectomy 
procedure.  
 Key Points: 
 There is a need for an expansion of providers able to oversee thrombolysis 
treatments. Advanced practice providers including nurse practitioners, 
telemedicine, and MSUs may help address this issue. 
 With the magnitude of benefit EVT confers on patients with AIS, and the resulting 
increase in need for proficient providers and suitable hospitals, there is a need to 
rethink hospital certification and training standards for NeuroIntervention. These 
standards, however, must be determined with the patients’ best interest in mind. 
 
 
4. Future of thrombolysis 
 
Combining with anticoagulation 
Andrew Barreto, Gary Ford, Opeolu Adeoye  
 
Current reperfusion therapy with IV tPA alone in acute ischemic stroke is only able to 
recanalize approximately 50% of occluded arteries and 15 to 35% of patients who received 
thrombolysis experience early reocclussion within the first 2 hours. Although 
thrombectomy achieves higher recanalization rates, it is not available at many countries 
and patients may not be eligible when they arrive at CSC. Augmentation of IV tPA through 
the use of anticoagulants may have a potential significant public health impact if early 
administered, removing the need for transfer to a specialized center. Argatroban and 
eptifibatide have demonstrated efficacy in 6 phase II clinical trials with higher 
recanalization rates, no association with an increased risk for symptomatic intracerebral 
hemorrhage, and an increase in excellent functional outcome at 3 months. More clinical 
trials will define dosage of this anticoagulants and contribute to the proven efficacy of this 
combination therapy. 
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Combining thrombolysis with other approaches including magnetic enhanced lytics, 
perfluorcarbon, otaplimastat and glyburide 
Keith Muir, Jong Kim, Taylor Kimberly 
 
Turbulent flow in the arterial segment proximal to the occlusion alters delivery of the 
thrombolytic agent to the blood clot surface, as rtPA can only diffuse passively. In vitro 
studies of Magnetically Enhance Diffusion through iron nanoparticles with an externally 
applied magnetic field accelerates clot lysis and is now being pursued as an adjunct to IV 
rtPA and endovascular treatment in the setting of LVO is being evaluated in phase II 
clinical trials.  
 
Perfluorocarbon nanoparticles are being studied in both transient and permanent MCAO 
models offering the potential to halt the evolution of ischemic damage by delivering 
oxygen to brain parenchyma beyond the site of occlusion and help to reduce infarct 
volumes. In addition, a phase II safety trial is evaluating the ability of this modality to 
provide imaging of the penumbra in combination with oxygen challenge (BOLD MRI).  
 
Otaplimast is a new antioxidant agent that decreases free radicals by inhibiting iNOS 
expression, possesses an anti-inflammatory action by inhibiting inflammatory cell 
migration, and has also exhibited blood-brain barrier stabilization by metalloproteinases 
deactivation. It has been studied in phase I and phase II clinical trials showing smaller 
growth of infarct size, improved outcome and no significant increase in hemorrhagic 
transformation. A phase II study had a small sample size, so further studies are needed to 
confirm the efficacy.  
 
An intravenous form of glyburide is under clinical development for the treatment and 
prevention of cerebral edema after a large hemispheric infarction. In an animal transient 
MCAO model of severe cerebral ischemia, glyburide reduces edema and hemorrhagic 
transformation, with similar findings observed when high-dose IV tPA was co-
administered at the time of reperfusion, with a more pronounced effect of IV glyburide on 
plasma MMP-9 and water uptake in the subgroup treated with IV tPA. These data highlight 
a potential effect of IV glyburide in combination with IV tPA and/or with EVT in the 
setting of severe ischemia. 
 
Discussion Panel 
Sean Savitz, Bruce Campbell, Alastair Buchan, Mitch Elkind  
 
In light of the recent successes with thrombolysis and thrombectomy, there is interest in 
reconsidering the role of neuroprotection and other strategies designed to limit reperfusion 
injury after stroke. It is unlikely, however, that the magnitude of benefit from these 
adjunctive therapies will be as large as those from thrombolysis or thrombectomy itself. 
Trials of such adjunctive therapies may therefore need to use trial approaches distinct from 
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those of the thrombolytic trials. Neuroprotection trials are likely to be require much larger 
sample sizes than thrombectomy trials. Alternatively, additional biomarker strategies could 
be used to identify patients most likely to benefit, and thereby improve trial efficiency. 
Imaging neuroinflammation or identifying serum-based biomarkers, such as complement 
levels, that predict a response to immunotherapy could help, for example.  
 
In addition, a reassessment of trial outcomes of interest, and the time of assessment, may 
also be of value. Recent epidemiological evidence has shown that after a period of initial 
recovery, stroke patients experience decline in function73 and cognition.74 Animal models 
of stroke similarly show delayed cognitive decline after stroke.75 Neuroimmune 
mechanisms, including the effect of infection occurring at the time of stroke, may 
contribute to this late decline.76 Thus, we may also want to consider assessing outcome 
measures distinct from crude handicap scores, such as the modified Rankin scale, for some 
therapeutic effects. It is possible that some therapies, when given early, will have more of 
an effect on preventing later problems with cognition, depression, or fatigue, and scales 
focused on these outcomes may be increasingly relevant in trials patients undergoing 
thrombolysis. Most acute stroke trials collect outcomes out to 90 days, moreover, but some 
of these effects may not be seen for many months or even years after treatment; thus, longer 
follow-up assessments may be increasingly relevant. 
 
The NIH have initiated the SNAP program to accelerate high quality preclinical stroke 
research using the principles of multi-laboratory reproducibility recommended in the 
STAIR consensus. Six laboratories with candidate molecules for stroke neuroprotection 
will be selected and each will test all 6 compounds in different stroke models with the most 
successful candidate taken forward into human clinical trials. 
 
Key Points: 
 Thrombolysis has experienced a number of recent successes, with preserved 
safety and efficacy in additional patient cohorts. Novel therapies that increase 
the efficacy of thrombolytics as well as freeze the penumbra and minimize the 
injury associated with reperfusion may continue this trend. 
 
 
 
New lytics in the pipeline including TNK, plasmin, TAFI inhibitor 
Carlos Garcia Esperon, Jeff Saver, Michel Piotin  
 
Tenecteplase is a genetically engineered recombinant tissue plasminogen activator that is 
currently the first line treatment for thrombolysis in myocardial infarction. In acute 
ischemic stroke TNK shows a pharmacokinetic advantage over alteplase, as it is given in a 
single dose as bolus instead of a continuous infusion with alteplase, and it has less risk of 
hemorrhagic transformation. Current clinical trials are being conducted to determine if a 
high-dose TNK is superior than a low-dose TNK, with the EXTEND-IA TNK II study 
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exploring whether 0.4mg/kg dose is superior to 0.25mg/kg in producing early reperfusion. 
There is also limited information of the use of TNK in the late window after 4.5 hours of 
stroke onset. Parsons et al77,78 showed in a small sample that both 0.1 and 0.25mg/kg dose 
of TNK had greater reperfusion than tPA up to 6 hours since onset (79% vs 55%, p=0.004) 
and similar sICH rate.  The TWIST trial will aim to test 0.25 mg/kg TNK in a wake-up 
population, but only with non-contrast CT selection. Future trials (under design) will aim 
to define the role of TNK in the extended time window with multimodal imaging selection. 
 
Future thrombolytic therapies in acute ischemic stroke 
Early recanalization of the occluded artery represents the current therapeutic goal of AIS 
management. Intravenous fibrinolysis using recombinant tPA infusion is the only approved 
drug therapy in AIS.  Recommended doses used in AIS lead to an increase of nearly 1000 
times the physiological blood concentration of t-PA. T-PA is the major intravascular 
plasminogen activator. It converts plasminogen to plasmin, which is able to cleave fibrin 
strands contained in a thrombus in small fibrin degradation products leading to 
thrombolysis. However, these treatments have important limitations. Because of numerous 
contra-indications, very few patients are eligible to and receive tPA-mediated thrombolysis 
(~5 % of AIS patients). Moreover, IV tPA is associated with an increased risk of 
hemorrhagic transformation and often fails to achieve successful recanalization, especially 
in the case of large vessel occlusions (LVO). In this context, different research ways to 
improve AIS thrombolysis have been recently developed.  
A first strategy could be to target circulating fibrinolysis inhibitors to increase the 
thrombolytic efficacy of IV t-PA.  
TAFI 
TAFI (thrombin activated fibrinolysis inhibitor) is the main circulating fibrinolysis 
inhibitor. Indeed, after activation by thrombin, thrombomodulin or plasmin, activated 
TAFI (TAFIa) is able to cleave C-terminal Lysine residues from fibrin networks, which 
prevents the formation of the ternary complex including plasminogen, t-PA and fibrin 
resulting in the inhibition of new plasmin generation. In blood samples during EVT using 
a microcatheter placed in contact to the thrombus, there is a local increase of activated 
TAFIa in patients previously treated with IV t-PA. This could contribute to t-PA induced 
thrombolysis resistance. In an experimental thrombo-embolic model of stroke, it was 
suggested that TAFIa inhibitor in association with suboptimal dose of t-PA was associated 
with a reduced ischemic lesion growth compared to full tPA dose. TAFIa alone, in this 
study had no impact.79 Regarding clinical studies, there are two ongoing phases 1-2 clinical 
trials assessing the safety of administering of a TAFIa inhibitor developed 
(ClinicalTrials.gov Identifier: NCT02586233 and NCT03198715). The first one is 
recruiting non-selected AIS with a primary endpoint of safety. The second one is focused 
on AIS treated by EVT with also a primary endpoint of safety. 
Von Willebrand Factor 
The second strategy to enhance thrombolysis in AIS is to target non-fibrin AIS thrombus 
components. These thrombi contain platelet aggregates. Platelet cross-linking during 
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arterial thrombosis involves vWF multimers.80 Therefore, proteolysis of VWF multimers 
appears promising to disaggregate platelet-rich thrombi and restore vessel patency in AIS. 
A first study from Denorme et al found that AIS thrombi contained about 20% of vWF. 
The authors suggested that targeting vWF with the specific VWF-cleaving protease 
(ADAMTS13) could exert a thrombolytic effect in an experimental thrombo-embolic 
model of stroke associated with a reduced infarct volume.81 
A more recent publication assessed a potent thrombolytic effect of N-Acetylcysteine 
(NAC, a clinically approved mucolytic drug). NAC has the ability to break-up VWF 
multimers by reducing intrachain disulfide bonds in large polymeric proteins. 
This publication founded an increased recanalization rate with NAC infusion compared to 
saline especially with concomitant treatment with anti-GPIIb/IIIa therapy, suggesting a 
synergistic action of these two treatments.82 
Neutrophil extracellular traps  
NETs (neutrophil extracellular traps) are an extracellular network of chromatin with double 
stand DNA from neutrophils. They exert a platform of coagulation activation and platelet 
aggregation.83 NETs contribute to the composition of all AIS thrombi especially in their 
outer layers. The presence of neutrophils and NETs in AIS thrombi were investigated by 
immunofluorescence analysis. Immunofluorescence detection confirmed that areas 
containing extracellular DNA colocalized with citrullinated histones and granular 
neutrophils proteins (such as myeloperoxidase), which correspond to NETs. NETs were 
constitutively present in all AIS thrombi.84 Ex vivo, recombinant DNAse 1 accelerated 
tPA-induced thrombolysis, whereas DNAse 1 alone was ineffective. Our results indicate 
that co-administration of DNAse 1 with tPA could be of interest in the setting of AIS with 
LVO.  
Future thrombolytic therapies will involve an optimization of fibrinolysis therapy with 
TAFIa inhibitor infusion for example. But, in our opinion, the most promising way consists 
of targeting non-fibrin contents of thrombi, especially, platelets, vWF and NETs. This 
reasoning supports a pharmacological “cocktail” for the future of AIS treatment including 
therapies targeting different contents of thrombi. The development of such add-on 
therapies may represent a unique opportunity not only to improve recanalization therapy, 
but also to reduce tPA doses and the associated risk of intracranial bleeding, which is 
responsible for an increased mortality rate in tPA-treated AIS patients.  
 
 
Do we need more exploration of dose? 
Craig Anderson, Phil Gorelick, Kazunori Toyoda   
  
Seminal dose-escalation studies of the US National Institute of Neurological Disorders and 
Stroke (NINDS) tPA study in the early 1990s determined a dose of 0.9mg/kg (10% bolus) 
of intravenous tPA, on the basis of both major neurological improvement and concomitant 
paucity of brain hemorrhage,85,86 for administration in the subsequent positive phase III 
clinical trials in acute ischemic stroke (AIS).87 The 0.9 mg/kg dose has become the standard 
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tPA treatment regimen for AIS in North America and much of the rest of the world, except 
in Asia, where lower doses of tPA are popular due to the: (i) perception of reduced major 
symptomatic intracranial hemorrhage (sICH), where the risks are considered higher in 
Asians; and flexibility of rounding to use of a single vial for reducing the cost of treatment 
in low resource settings.   
 
Japan was one of the last countries to approve the commercial use of alteplase in AIS in 
2005 but at a dose of 0.6 mg/kg, based on data from a dose-comparison study of duteplase88 
and the multicenter single-dose Japan Alteplase Clinical Trial.89 Post-marketing studies, 
including the nationwide Japan post-Marketing Alteplase Registration Study (J-MARS)90 
and the multicenter Stroke Acute Management with Urgent Risk-factor Assessment and 
Improvement (SAMURAI) rt-PA Registry,91 have shown similar efficacy and safety of 
alteplase at 0.6 mg/kg as compared the standard-dose of tPA among AIS patients registered 
with the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST) 
in Europe.92 
 
The only randomized evaluation of low-dose versus standard-dose alteplase has been in 
the international Enhanced Control of Hypertension and Thrombolysis Stroke Study 
(ENCHANTED). This large trial failed to clearly show non-inferiority in the primary 
outcome of death or disability, defined by conventional poor outcome scores 2 to 6 on the 
modified Rankin scale (mRS).93  The results were likely due to insufficient power for the 
stringent non-inferiority margin imposed, as the ordinal shift analysis of the full range of 
mRS scores was significant for non-inferiority.  Just as important, though, were the 
findings that sICH was halved, which translated into significant lower mortality at 7 days, 
in the low-dose group. 
 
Overall, the evidence from observational studies, systematic reviews and meta-
analyses,94,95 is consistent in concluding, either of no clear difference or in favor of 
improved outcomes and reduced sICH with low-dose tPA.  The findings are consistent in 
sensitivity analyses by fixed dose comparisons and in studies confined to Asian 
populations.     
 
Our conclusions are that low-dose tPA offers lower cost, reduced bleeding risk particularly 
of sICH, and near non-inferiority in relation to efficacy compared to standard-dose tPA. 
Because use of low-dose tPA has been the subject of considerable evaluation in many 
Asian countries, clinicians there are likely to be more amendable to the utilization of this 
treatment. However, given the considerable challenges to accepting standard-dose tPA that 
have existed in many sectors of North America, and based on the interpretation of current 
evidence in the context of the FDA-approved dose, it may be difficult in successfully 
arguing in favor of using low-dose tPA outside of Asia.   
  
Discussion Panel 
Greg del Zoppo, Steve Davis, Ritvij Bowry, Ken Uchino   
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The potential of bolus-injection tenecteplase (TNK) replacing alteplase is based on the 
NORTEST trial (0.4 mg/kg TNK), which showed similar benefits in a mild stroke 
population.  The EXTEND TNK trial showed that tenecteplase (0.25 mg/kg) compared 
with alteplase doubled reperfusion rates when administered before thrombectomy and was 
associated with improved clinical outcomes. An ongoing Phase III trial, TASTE, involves 
a head-to-head comparison of these thrombolytic agents.  Regarding practical matters, the 
panel commented on the pricing of these agents which needs to be considered in the context 
of delivering these drugs across the world in specific markets such as USA, Europe, Asia 
and Australia. The major barrier to worldwide TNK or alteplase use includes its current 
lack of approval by influential regulatory bodies, such as the FDA. It is hoped that ongoing 
clinical trials of TNK will provide strong scientific evidence of its efficacy that will 
facilitate overcoming this barrier.  Others raised concerns regarding the manner in which 
new thrombolytic agents might fit into clinical practice, and the contributions of clinical 
research protocols to these efforts. If the role is to dissolve thrombi before endovascular 
procedures, the time from infusion to puncture at comprehensive stroke centers is short and 
the capacity of drip-and ship facilities to conduct research is limited. Performing this 
research in the current infrastructure will be challenging, and would require novel 
approaches including remote electronic consent, or waiver or deferral of informed consent, 
telemedicine evaluation, and pre-hospital delivery of agents in a research setting. 
 
In this context, the development of a new approach to intravenous thrombolysis will come 
under test.  Recent work has demonstrated that t-PA exposes cleavage sites on fibrin so 
that pro-UK can bind and effect local plasminogen activation, and thrombus lysis.  This 
approach will be tested prospectively for safety in patients presenting within 4.5 hours from 
symptom onset whereby t-PA (0.9 mg/kg) will be directly compared with low dose t-PA 
(5 mg) followed by the mutant Hispro-UK over 60 minutes in a phase II trial.  Mutant 
Hispro-UK resists inhibition. It is expected that a lower incidence of intracerebral 
hemorrhage will be demonstrated, given the lower dose of t-PA.  A published trial in acute 
myocardial infarction has demonstrated safety of the combination with comparable 
efficacy to t-PA. 
 
 Key Points: 
 Newer thrombolytic agents including TNK, as well as future targets that 
enhance thrombolytic treatments may improve recanalization rates, and reduce 
hemorrhage. 
 Low-dose tPA offers lower cost, reduced bleeding risk and near non-
inferiority in relation to efficacy compared to standard-dose tPA.  On the other 
hand, given the considerable challenges to accepting standard-dose tPA, it 
may be difficult in successfully arguing in favor of using low-dose tPA 
outside of Asia.   
 
5. Future of thrombectomy  
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Summary of new data from clinical trials of thrombectomy since ISC or ESOC 
Tudor Jovin 
 
BEST Trial 
The Basilar Artery Occlusion Endovascular Intervention versus Standard Medical 
Treatment (BEST) trial is a multicenter, prospective, randomized, controlled, open-label 
trial with blinded assessment of end points. Participants were allocated, in a 1:1 ratio, to 
receive endovascular treatment plus standard medical therapy (intervention group) or 
standard medical therapy alone (control group). Based on its pre-specified intention-to-
treat analysis, the BEST trial failed to demonstrate a benefit of mechanical thrombectomy 
over medical therapy alone in the treatment of BAO within 8 hours of estimated occlusion 
time. After enrollment of 131 patients (66 in the intervention group, 65 in the control group) 
from April 2015 through September 2017, the study was terminated prematurely by the 
steering committee according to the recommendation of the DSMB due to excessive 
crossovers and progressive drop in valid recruitment. Results may have been confounded 
by the fact that equipoise was lost over the course of the study as demonstrated by the high 
cross-over rates and progressive drop in valid recruitment which eventually led to the early 
termination of the trial. Notably, patients who were actually treated with thrombectomy 
had significant better outcomes for all the primary and secondary functional endpoints on 
adjusted analysis. 
 
A Trial Comparing Transfer to the Closest Local Stroke Center vs Direct Transfer to 
Endovascular Stroke Center of Acute Stroke Patients with Suspected Large Vessel 
Occlusion in the Catalan Territory (RACECAT) is a prospective, multicenter, cluster 
randomized controlled, open, blinded-endpoint trial of acute stroke patients with suspected 
acute large vessel occlusion (LVO) identified by EMS at first assistance on the field, in 
which two strategies are compared: transfer to the closest local stroke center (Local-SC) 
against direct transfer to an endovascular stroke center (EVT-SC). The current enrollment 
up to October 2018 is of 736 subjects.  
 
AURORA Consortium 
One would naturally anticipate that the benefits of a reperfusion therapy would be markedly 
diminished if treatment is delayed for many hours after symptom onset. Yet, the late 
window thrombectomy trials, DAWN and DEFUSE 3, reported treatment benefits that are 
larger than seen in the early window trials; this has been termed the “Late Window 
Paradox”. The critical factors that explain the paradox are (1) about half of the patients 
with large vessel intracranial occlusions have very slow growth of the ischemic core for up 
to 12 hours or longer; (2) the favorable collateral circulation that is responsible for keeping 
the ischemic core size small eventually fails in most patients and infarct volumes ultimately 
increase; and (3) clinical outcomes in the control groups of the randomized trials are 
strongly influenced by whether or not tPA was administered. Recent data from DEFUSE 
3 suggest that for about 20% of the medical control group, a favorable imaging profile 
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persists for up to 40 hours after last know well times. The “time is brain” concept requires 
a revision that allows the fortunate patients who have favorable collaterals and slow infarct 
growth to receive reperfusion therapy even in very late time windows. However, because 
it is not possible to immediately determine the growth rate of the ischemic core, it remains 
critical to evaluate and treat all stroke patients as urgently as possible.  
 
 
Expanding candidates-later time window, milder strokes, large core, distal and 
posterior circulation 
Greg Albers, Jay Mocco, Joey English   
 
The anticipation of lack of benefit from reperfusion therapy in patients presenting after 
more than 6 hours from symptom onset was questioned by the trials DAWN and DEFUSE 
3, which reported larger treatment benefit over patients treated in the early window trials. 
This late window paradox may be explained by the slow growth of infarct core in patients 
with LVO, the favorable collateral circulation and the influence of whether tPA was 
administered or not in the control group of RCT. With this evidence, time is becoming less 
of an exclusion criterion to allow patients who have favorable collaterals and slow infarct 
growth to receive reperfusion therapy in the late time window.  
 
One of the most challenging stroke population are that of patient presenting with a low 
NIH Stroke Scale regardless of the ASPECTS or other neuroimaging characteristics, 
especially when it comes to the risk of therapy.  About 50% of AIS patients present with 
minor stroke symptoms (MSS), with 70% of these patients not undergoing vessel imaging, 
and one quarter of MSS patients end up with a poor outcome.96 Early neurological 
deterioration (END) develops in 23-41% of patients, and is associated with a worse 
outcome up to 60% of patients.97   
The presence of a large vessel occlusion increases the risk for END by 2-fold and is found 
in 40% of patients with END.98 MSS-LVO is associated with a 7-fold risk of poor outcome 
compared to MSS without an LVO, a 6% in overall mortality, and if left untreated, 32-45% 
have a poor outcome.99 Sarraj et al100 looked at 124 EVT and 90 medical patients with an 
MSS-LVO and determined there was an OR of 2.7 OR for good outcome in patients with 
ICAT and M1 occlusions, but distal occlusions showed no difference between treatment. 
Early rescue intervention showed a better outcome in 75% of patients when compared to 
delayed IAT, in which only 33% of patients had a good outcome.101 IAT protects against 
END but it was found that the risk for intracranial hemorrhage was 12%.101  
 
Currently, around 20% of patients in routine practice are being treated for M2 
occlusions.102 From the HERMES collaboration, only 94 patients had M2 occlusions but 
there is still a need for data that proves clear benefit from therapy. Good recanalization and 
good outcome were observed in about 60%, but the symptomatic intracranial hemorrhage 
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rate was 10%, higher than other trials.17 Unfortunately, coverage from insurances varies 
between states, and some deem treatment for M2 occlusions to not be medically necessary. 
Regarding the BEST trial, there was a conclusion that a basilar occlusion was best left 
untreated. Currently posterior circulation strokes are being treated, and it represents 10% 
of all thrombectomies.103 More data regarding the natural history, risks factors and 
outcomes is required but RCT lack clinical equipoise to be conducted, which makes this 
challenging. Contrary to M2 occlusions, treatment of basilar occlusions is considered only 
investigational and not medically necessary across all states. 
 
Discussion Panel  
Raul Nogueira, Aneesh Singhal, Reza Jahan, Alex Abou-Chebl   
 
The benefit of thrombectomy can be expanded by investigating more subgroups, increasing 
community access, and developing adjunctive treatments. Investigation of various 
subgroups that may still benefit (e.g. large core, late time window) will require numerous 
trials and was discussed at length. It seems a lengthy and expensive process -- our tax 
dollars may be better spent ironing out “access” issues! In specific, the relatively low 
volume of thrombectomy precludes 24/7 coverage outside of academic medical centers; 
expanding the pool of interventionalists carries the risk of cardiac interventionalists ‘taking 
over’ thrombectomy with limited knowledge about stroke. One solution is to dissociate the 
technical (procedural) component from the decision-making component, with the latter 
restricted to stroke neurologists, and ensuring that compensation favors the decision-
making component. Under this scenario thrombectomy could be expanded to the 
community by allowing interventionalists of any background (neurology, cardiology, 
radiology) to do the actual procedure, provided there is onsite or remote (telestroke) 
supervision by a stroke neurologist. This model would allow faster and widespread IA 
access, be economically viable for the smaller hospitals, and ensure a minimum quality of 
care. Neuro-interventionalists would receive both the technical and decision-making 
component. Other proceduralists will receive only the technical component and will require 
a minimum amount of cerebrovascular thrombectomy training. Other neuro-IR procedures 
such as aneurysm coiling would be restricted to neuro-interventionalists. Vascular 
neurologists would be more fairly compensated for their role in thrombectomy.  
Adjunctive strategies include freezing the penumbra through neuroprotection. We all agree 
that the drug or strategy should be compatible with tPA as well as TNK, feasible to 
administer within a narrow time window (ideally pre-hospital), and safe in stroke 
mimicsGoing forward we need to be much less ambitious about effect size and reconsider 
outcome measures. The strategy of penumbral freezing with hypothermia, hyperoxia, etc. 
may require outcomes looking at ‘immediate benefit’ in addition to long term benefit at 
least in phase 2 trials -- confirmation of immediate benefit is important since early trials 
may not be adequately powered to show long term benefit. We need to better understand 
whether neuroprotection is more beneficial in “slow progressors” (i.e. milder strokes) or in 
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“rapid progressors” where even thrombectomy’s benefit is controversial. Existing 
CTP/MRP criteria are optimized for selecting patients for thrombolysis/thrombectomy; for 
patient selection for neuroprotection, revised ADC or perfusion-imaging thresholds may 
be needed to identify less severe or even reversible ischemia. Lastly, with the ongoing 
national debate about drug pricing, the cost of drug development (trial size) will have more 
stringent limits and we may not have capacity to fail in mega-sized trials. 
 
Key Points: 
 Recent data, and upcoming trials, are expanding the indication for thrombectomy 
to broader groups of patients, including those with larger infarcts at presentation 
and presenting in later time windows. 
 Adjunctive strategies including neuroprotection will receive a resurgence in this 
paradigm, as our ability to revascularize occluded vessels improves, and the need 
to “freeze the penumbra” becomes more relevant. 
 With these thoughts in mind, however, access to EVT remains a key priority and 
perhaps a more important target for clinical trial investigation. 
 
 
 
Technological advances in devices 
Michel Piotin, Olvert Berkhemer  
 
LVO pre-hospital detection 
The benefit of EVT is highly time dependent, and every hour delay decreases the chance 
of functional independence by 20%.32 Delivery of a patient eligible for mechanical 
thrombectomy to a non-thrombectomy center costs an average of 110 minutes.30 Current 
existing triage methods relying on stroke severity clinical scales are lacking of sensibility 
and specificity to detect LVO.104 Technology that could achieve similar speed, but with 
better sensitivity and specificity for LVO would have the potential to improve the rapidity 
of care. The volumetric impedance phase shift spectroscopy (VIPS) device experienced 
initial positive findings.105 The system is placed on the patient’s head for one minute, and 
utilizes VIPS to measure hemispheric asymmetry of the brain, correlating with severe 
stroke. Further validation studies are warranted to conclude if this device could be used in 
regular clinical setting. 
 
New stent retrievers and aspirations devices 
The recent development in stent retriever technology aimed at augmenting the “first pass 
effect,” meaning obtaining a faster satisfactory reperfusion status (mTICI≥2b) and 
diminishing the rate of clot embolus into previously unaffected vascular territories. To do 
so this new generation of stent retrievers are designed to better conform to the vasculature, 
a key factor linked to the risk of thrombus fragment losses during the pullout phase of 
mechanical thrombectomy with stent retriever. Manufacturers are also developing larger 
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bore aspiration catheters as the aspiration technique (with or without the joint use of a stent 
retriever) is gaining wider acceptance.106 
 
Regional cooling and other neuroprotection including NA-1, Uric acid 
Michael Hill, Y Ding, Angel Chamorro 
 
Therapeutic hypothermia has proven to offer neuroprotection and has significant potential 
in improving clinical outcomes due to multiple synergistic effects on decreasing damage 
from ischemia and reperfusion. Hypothermia slows pathways that cause excitotoxicity, 
apoptosis, inflammation and free radical production, as well as blood flow, cerebral 
metabolism and blood–brain barrier integrity. However, its clinical use has largely been 
limited due delayed cooling onset, prolonged duration to achieve a lowered core 
temperature, extensive medical and nursing efforts, as well as secondary complications. 
Previous studies have shown that the infusion of cold saline, i.e. intra-arterial regional 
cooling infusion (RCI), is a feasible technique for inducing selective hypothermia during 
endovascular treatment of intracranial occlusion and confers neuroprotection in ischemic 
stroke. RCI combined with endovascular recanalization can be safely achieved, leading to 
potential neuroprotection, in acute ischemic stroke patients. Future research will help to 
determine whether neuroprotection is beneficial in “slow progressors” (i.e. milder strokes) 
or in “rapid progressors” where even thrombectomy’s benefit is controversial. 
  
Pharmacological treatments or mechanical thrombectomy are frequently powerless to fully 
reperfuse the ischemic brain despite achieving a high rate of recanalization. Former 
experimental models of transient brain ischemia identified the lack of reflow at the brain 
microcirculation despite complete recanalization of proximal arterial occlusions. More 
recently, oxidative and nitrosative stress were found to play a major role in “no reflow” as 
the result of a rich expression of pro-oxidant NADPH oxidases (NOX) in brain 
endothelium, vascular smooth muscle, adventitia and capillary pericytes. Other sources of 
high concentrations of reactive species included the mitochondria, the activity of 
cyclooxygenase enzymes, NOX expressed by neurons, and infiltrating neutrophils, and the 
hypoxic-dependent conversion of xanthine dehydrogenase (XDH) into xanthine oxidase 
(XO). Amongst the more than 4000 free radicals or non-radicals which have been 
described, peroxynitrite is an especially attractive molecular target for therapeutic 
intervention because is highly toxic, it crosses readily biological membranes, and interacts 
with most critical bio-molecules. Likewise, under experimental conditions peroxynitrite is 
largely generated in the ischemic penumbra where it builds up for about 6 to 12 hours, thus 
giving strong biological rationale and a realistic time window of opportunity for therapeutic 
intervention.  Uric acid (UA) is a potent peroxynitrite scavenger whose safety was 
demonstrated in a cohort of 421 patients treated with alteplase within 4.5 hours of stroke 
onset in the URICOICTUS trial. A preplanned nested study of the URICOICTUS trial 
showed that UA therapy showed a 19% absolute increase in the proportion of good 
outcome compared with placebo in patients who in addition to intravenous alteplase also 
received rescue mechanical thrombectomy. The ease of UA administration (a 90-minute 
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intravenous infusion during the endovascular procedure) and long elimination half-life of 
44 hours (one single administration), are additional advantages of this treatment modality 
that deserves appropriate validation in a larger confirmatory trial of stroke patients with 
LVO treated with mechanical thrombectomy.   
 
NA-1 is a small eicosopeptide (20 amino acids) constructed from components of the NR2b-
subunit of the NMDA receptor and HIV envelope protein TAT.  The TAT protein moiety 
allows easy passage across a lipid bilayer and across the blood-brain barrier.  The NR2b 
subunit moiety is analogous to the binding site of a PDZ-binding domain for a series of a 
catalytic protein on the cytosolic surface of the receptor.  Competitive inhibition of the 
binding site prevents activation of the protein cascade, that is triggered by calcium entry 
through the VGCC function of the NMDA receptor, that results in intracellular production 
of nitric oxide. 
 
NA-1 was tested in multiple animal species including old-world primates (cynomolgus 
macaques) and in a phase 2 study in humans undergoing aneurysm coiling.  The ESCAPE-
NA1 study is 50% enrolled and attempting to demonstrate efficacy of NA-1 in human 
stroke using a paradigm that mimics the cynomolgus macaques experiment.   
 
Discussion Panel 
Enrique Leira, Bernard Yan, Julian Bosel, Thabele Leslie-Mazwi   
 
The panel agreed that further progress is needed in the devices used for mechanical 
thrombectomy. An important feature for new devices should show improved effectiveness 
(e.g rate of TICI 3), including speed and simplicity of use in achieving successful 
reperfusion (e.g. at first pass). Current devices are suited for embolic thrombus however 
none are designed to address intracranial atherosclerotic disease, an entity that to this day 
remains poorly treatable. Metrics that allow greater comparison between devices (first-pass 
effect, mTICI 3 reperfusion result, etc) will allow small differences in devices to be better 
understood, but the diversity of patient anatomy and vascular occlusion requires a range of 
device options remain available. Approaches to improved device-based reperfusion should 
be broader than simply clot-device interaction, including base catheter systems and a full 
evaluation of intra-arterial lytic options.  
 
Penumbral imaging may help selection of the best patients for clinical trials to evaluate the 
use of neuroprotection in the thrombectomy setting, as current research fails to adequately 
rank the merit of these interventions. The concept of combined neuroprotection (i.e. 
sequence of different substances for different phases of stroke and/or different settings such 
as ambulance and angio-suite) is appealing. However, the challenge to transfer preclinical 
data, including that of the potential interaction of these agents, to the corresponding clinical 
setting, deserves more prospective research as by pilot studies. 
 
Key Points: 
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 New devices for thrombectomy are being developed and should focus on 
effective reperfusion on the first pass. The definition of device superiority, 
relative to existing devices, however, is unclear. Further, the interaction 
with these devices on intracranial atherosclerosis, a disease that remains 
poorly treated, should be addressed. 
 Neuroprotective strategies including NA-1, uric acid, and hypothermia have 
shown some success, raising the question of the profile of patient (i.e. 
penumbral status) in whom they will be the most effective. 
 
 
 
 
Imaging selection—how will we reach a consensus on imaging selection? 
Bruce Campbell, Amrou Sarraj, David Liebeskind   
 
Some of the key controversies in the field of stroke imaging are if acquiring more than 
NCCT/CTA in patients is beneficial and if CTP/MRI is obtained how will imaging 
influence in reperfusion decisions. The concept of patient selection within the 0-6hr time 
window based on any single clinical or imaging parameter is naïve. HERMES meta-
analyses of the positive endovascular trials have indicated consistent treatment effect 
across a broad range of age, clinical severity, non-contrast CT ASPECTS, CTA collaterals, 
CTP/diffusion MRI ischemic core volume etc. All these factors are, however, strongly 
prognostic and the presence of multiple negative prognostic features may lower the 
absolute probability of meaningful outcome sufficiently to justify regarding reperfusion as 
“futile”.   
 
The choice of imaging strategy for diagnostic and prognostic purposes needs to be 
distinguished from selection criteria used to determine eligibility for endovascular 
thrombectomy. Performing a CT perfusion scan does not imply or require any particular 
selection criteria for thrombectomy. Indeed, advanced imaging is not simply about 
excluding patients from thrombectomy. It can also include more patients and provide 
diagnostic benefits. Despite the positive trials of reperfusion >6hr all using CT perfusion 
or MRI selection, there are attempts to simply use non-contrast CT for selection in the late 
window on the grounds that this will expand the population who benefit. However, many 
patients are not at the extremes of excellent or very poor non-contrast CT appearance. In 
the intermediate zone there are patients who would be excluded by an ASPECTS threshold 
yet who would have met ischemic core volume<70mL criteria due to the poor volumetric 
correspondence and inter-rater variability with ASPECTS rating. Synthesizing the non-
contrast CT and CT perfusion information is likely to provide more informed decision-
making and improve the inter-rater reliability. Rather than accepting arguments around 
expertise, equipment, cost and treatment delay that are often provided as justification for 
not performing more advanced imaging, the field needs to find creative solutions to bring 
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more informative imaging to routine practice in both primary and comprehensive stroke 
centers. 
 
Future imaging to help selection; new sequences; new physiologic information 
Chris Levi, Steve Warach, Alexander Thiel   
 
The field of acute stroke reperfusion therapy is undergoing a paradigm shift.  The screening 
and selection criteria for treatment have evolved from being primarily driven by the time 
from last known well, the window for which closed at 4.5 hours, toward an approach that 
prioritizes the identification of patient-specific, treatment-related biological targets, by 
which treatment efficacy is less dependent on the time elapsed from last known well to the 
initiation of treatment.  Thus, the succinctly stated principle that clinical efficacy of 
reperfusion therapy in ischemia is time dependent (‘Time is Brain’) requires an updating 
and qualification. 
In considering reperfusion therapy for ischemic stroke, the time elapsed from last known 
well to initiation of treatment is not the most important predictor of benefit from 
thrombolysis or thrombectomy. Further, reperfusion treatment opportunities are better 
defined by the demonstration of a treatment relevant acute ischemic target than by the time 
from last known well. In addition, the duration and severity of focal cerebral ischemia in 
viable, vulnerable, and salvageable tissue determines the probability of infarction. Finally, 
in the presence of an ischemic target, the clinical efficacy of reperfusion is time dependent. 
Consensus statements of imaging selection and outcomes in stroke clinical trials issued by 
the Stroke Imaging Research (STIR) international collaborative107-109 have recognized the 
need for standardization in image acquisition and analysis as well as the importance image 
data pooling and sharing.  The STIR/VISTA-Imaging stroke MRI repository has been one 
such effort available to the community of stroke researchers 
(http://stir.dellmed.utexas.edu/).  STIR’s 2007 call for development of a tool for standard 
imaging processing of CT or MR images, vendor neutral, to reliably identify core and 
penumbra within the time constraints needed to assist in treatment decisions107 encouraged 
and energized the efforts resulting in RAPID, the software that has been central to the 
success of the recent clinical trials that broke through the early time windows. 
The most important advances on the horizon for imaging will not be so much the 
development of new scanning techniques, but rather in the pooling of large datasets to best 
define the limits of image-based treatment target selection and in disseminating the 
advanced clinical image methods to the centers where patients are assessed for acute stroke 
intervention. 
“Big data” to accelerate definition of patient profiles 
Compared to large-scale imaging network initiatives in other areas of neuroscience 
(Human Connectome project, Human Brain Project) and clinical neurology (ADNI, 
Autism research), the acute stroke imaging community is presently underutilizing pooled 
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imaging data analysis to advance the development of patient selection for individualization 
of acute stroke therapy. Although the need for imaging-data repository has been identified 
in the past107-109, present initiatives (STIR-repository, VISTA-imaging) suffer from  several 
challenges: the numbers of data-sets are small (several hundred), processed rather than raw 
data are archived, data have been acquired in the context of sponsored clinical trials using 
standardized acquisition protocols within but not necessarily between trials, and the 
reluctance of clinical trial initiatives to share data for pooled analysis. As a consequence, 
imaging research in the field has mainly been correlational110-112 not drawing on the 
strength of modern event-causal modelling approaches which have recently been used 
successfully to define e.g. “therapeutic fingerprints” of individual patients in other fields 
of clinical neuroscience.113 Defining patient profiles for therapy selection, consisting of 
imaging, demographic and medical parameters has been identified as a research priority. 
Driving this process by animal experiments, pilot studies and subsequent RCT’s however 
is inefficient with respect to time, resources and cost, given the large parameter space to be 
explored. Highly efficient parallel processing on distributed neuroimaging platforms like 
CBRAIN114 can identify and test the validity of identified profiles in several thousands of 
imaging and behavioral data sets thus accelerating the transition to clinical use compared 
to traditional development cycles.        
Implementing ischemic target definitions  
There is now sufficiently robust evidence to support more widespread adoption of imaging-
based selection for reperfusion therapies in routine practice, both in the hyperacute and 
extended time window situations. Additional refinements such as clinical decision 
assistance underpinned by accurate predictive algorithms for reperfusion therapy response 
will develop using “big data mining” and artificial intelligence approaches as described 
above. However, the history of research knowledge translation suggests that adoption of 
both the current and the future evidence will require the establishment of an international 
portfolio of implementation research projects in advanced stroke imaging, all aiming to 
avoid the often quoted on-average 17-year latency in translation of clinical discoveries into 
routine practice.  There is now a major opportunity for the stroke research community to 
begin to engage in and focus on a research agenda aiming at the development of locally 
effective strategies for adoption and diffusion of the emerging new knowledge in acute 
stroke imaging science. This will require the establishment of interdisciplinary teams that 
span radiology, imaging science, computer science, vascular neurology, implementation 
science and health service management. Ideally, it would also involve the formation of 
international consortia to share methodological knowledge, implementation enablers and 
knowledge and skills and have proven effective in achieving adoption across a variety of 
health systems. 
 
 
Discussion Panel 
Michael Hill, Jean Marc Olivot, Teruyuki Hirano, Albert Yoo    
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Multimodal imaging could be an important help for the diagnosis of acute brain infarction 
by non-vascular specialist in remote places and may therefore help to increase the number 
of cases treated. Due to the limited reliability of the ASPECTS score to assess the volume 
of the infarct core in the first hours after cerebral infarction, and regarding the last 
publication from HERMES investigators, future stroke trial investigating the benefit of 
thrombectomy among patients with "large infarctions" may rather use objective core 
volume measurement than low ASPECTS. Such approach will therefore give a robust 
demonstration of the benefit of thrombectomy in that subset of patient. 
 
Key Points: 
 Given the enormity of the effect size seen in endovascular trials using advanced 
imaging, in practice, treatment criteria (i.e. infarct size at presentation) may need 
to be relaxed to allow maximal benefit to patients with AIS. 
 Deciding which imaging study is optimal in screening patients is important, but 
ultimately these studies are supportive tools. Practical considerations, in terms of 
availability may be the greatest deciding factor for imaging protocols. 
 There continues to exist a need for large AIS imaging databases for improved 
understanding of target definitions and patient profiles. 
 
6. Speeding thrombolysis and thrombectomy 
 
How can we expand telestroke and other innovations? 
Teddy Wu, Lee Schwamm, Larry Wechsler 
 
Stroke is a rare event, accounting for less than 5% of emergency medical dispatches, 
emergency department visits and hospital admissions. Telestroke extends the reach of acute 
stroke expertise to rural and community hospitals increasing appropriate delivery of 
thrombolytic therapy and identifying patients eligible for mechanical thrombectomy.  Most 
telestroke networks limit evaluations to the acute stroke setting either in the emergency 
department or in-house stroke alerts.  When patients remain at originating hospitals after 
acute evaluation subsequent hospital care may not be the same as care delivered by vascular 
neurologists at a stroke center. Providing telestroke follow-up throughout the episode of 
care for stroke patients promotes efficient and cost-effective testing and selection of 
optimal treatment, reducing length of stay and improving outcomes. 
 
Advancement of stroke care is dependent on completion of clinical trials.  Traditional ways 
of patient recruitment into acute ischemic stroke trials at tertiary care centers can be 
inefficient and often patients at remote hospitals lack access to such trials.  Transfer delays 
from remote hospitals to larger tertiary centers may preclude enrollment of these patients 
into time-sensitive acute stroke clinical trials.  Telemedicine has the potential to enable 
stroke specialist to conduct acute stroke trials at remote hospitals to potentially enhance 
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enrollment while also increasing access and opportunities for stroke patients at rural and 
community hospitals to receive promising new therapies.  
 
 
Mobile Stroke Units—status and future perspective 
Klaus Fassbender, Steve Davis, Anne Alexandrov 
 
Staffing on mobile stroke units varies among existing programs, and is dependent on 
manpower availability, technology requirements, and regulatory and credentialing 
mandates. Programs should consider models that are sustainable based on personnel 
expense and the local availability of expertise.  Most countries and local governing 
authorities will require at least the presence of a licensed prehospital provider, such as a 
paramedic and/or emergency medical technician on board any vehicle that is licensed as 
an ambulance. Computed tomography (CT) technologists are required to perform all CT 
imaging acquisition functions. The main difference between MSU program staffing lies in 
the area of stroke expertise, with use of vascular neurologists, nurse practitioners, or 
telemedicine operations. Regardless of the staffing model utilized, MSU teams must 
collaborate closely to support optimal stroke diagnostic and treatment outcomes. 
 
Discussion Panel 
Martin Ebinger, Sandy Middleton, Silke Walter 
 
The discussion evolved around the role of nurses in future stroke care. Patients cared for 
in stroke units who received facilitated implementation to manage fever, hyperglycemia 
and swallowing using the FeSS Protocols (fever, sugar, swallow) had 16% reduced death 
and disability115, with a sustained effect in terms of 20% increased likelihood of being alive 
out to a median of four years.116 It also has been shown to result in a $AUD 281M saving 
if only 60% of all eligible patients received this care over 12 months. This is as a result of 
evidence-based nursing care. Further, stroke unit coordinators, most usually nurses, have 
been shown to improve uptake of evidence-based stroke care and improve patient 
outcomes.117 However, the QASC Europe study is demonstrating the variable level of 
autonomy of stroke nurses across the world. Advancing stroke nursing care requires active 
support by neurologists. How can neurologists advance the role of the stroke nurse within 
their services? Can they identify nurses with potential who could lead FeSS protocol 
implementation and support introduction of other evidence-based stroke care processes to 
improve patient outcomes?  
 
Involving stroke nurses in MSUs would support autonomy of nurses and strengthen their 
role in the service.22,118 In addition, a recent good example of the multifaceted uses of 
MSUs took place in Houston in 2017, when Hurricane Harvey caused power breakdown 
of a hospital. The Mobile Stroke Unit partly replaced the emergency department in this 
exceptional situation providing head CT imaging. This report sparked fantasies about 
Mobile Stroke Units replacing Stroke Units in underserved areas, though the panelists also 
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reminded the audience that a Stroke Unit is more than the CT-scanner and a laboratory. 
Apart from nurses and doctors, Stroke Units consist of a dedicated team that also includes 
physiotherapists, occupational therapists, speech therapists, and social workers. 
 
Key Points: 
 Telemedicine and MSUs shrink the gap between patient, provider, and treatment. 
 Nurses and advanced practice providers are well suited for deployment in these 
roles.  
 
Other approaches to increasing perfusion  
Andrei Alexandrov, Italo Linfante, Rolf Blauenfeldt  
 
The principle behind remote ischemic conditioning (RIC) is based in applying short-
lasting, non-lethal ischemia in a distant tissue to protect against long-lasting ischemic 
injury. In practice, it is applied by holding pressure to the target tissue for 5 minutes, and 
then allow a reperfusion stage for 5 minutes. These 2 stages are one cycle, and it is then 
repeated for a total of 5 cycles. RIC seems to target multiple neuroprotectants and cause an 
anti-inflammatory shift, as showed in many preclinical studies.119 
 
Ongoing RIC Trials 
1. RICA– This clinical trial is being conducted in China. It is the largest trial looking 
at a population with either AIS or TIA with symptomatic ICAD. Patients are treated 
with RIC once daily for one year and were then followed up to assess for stroke 
recurrence. Sample size is 2600 with its enrollment almost completed. Results are 
expected to be published in 2020. 
2. RESCUE BRAIN – Clinical trial in France, with 10 participating centers where 
RIC is given within 6 hours from symptom onset in the in-hospital setting for AIS 
patients treated with either tPA or IAT. Primary endpoint is infarct growth rate and 
enrollment has been completed. Results are expected early in 2019. 
3. REMOTE-CAT – Pre-hospital trial in which RIC is started within 8 hours from 
symptom onset in the ambulance. Target population is AIS patients who do or don’t 
receive reperfusion therapy. Primary endpoint is dichotomized modified Rankin 
scale.   
4. ReCAST-2 – Dose escalation study in the UK looking at the application of RIC in 
the in-hospital setting for AIS patients. Enrollment has been completed and results 
will be analyzed for planning of a large efficacy trial (ReCAST-3). 
5. RESIST – Danish trial for pre-hospital RIC given within 4 hours from symptom 
onset in patients presenting with stroke symptoms. If patients are confirmed of 
having an AIS or ICH, patients are treated once again in-hospital after 6 hours. 
Current enrollment is 170 patients out of 1500 patients.  
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The effect of improved functional outcome is likely to be small, but RIC treatment is a 
cheap and feasible therapy without serious adverse events risk. Questions regarding which 
subset of patients will benefit from this intervention, and standardized timing and dosing 
of cycles are yet to be answered.  
 
Recent data showing increasing blood flow in the leptomeningeal anastomosis by 
administering Hemoglobin Oxygen Carriers and Carboxyhemoglobin Transporters in 
Middle Cerebral Artery Occlusion (MCAO) may represent a way to slow down core 
progression by increasing collateral circulation and transporting oxygen in acute ischemic 
brain tissue. 
 
Sonothrombolysis is another approach for improved thrombolytic efficacy.  
CLOTBUSTER (NCT01098981) had a signal of efficacy for in subgroup analysis 
(publication pending). A new phase III international trial called TRUST (NCT03519737) 
will include patients diagnosed with large vessel occlusions by CT-angiography who will 
also be eligible for intravenous tPA treatment within conventional time window at spoke 
hospitals and transferred for mechanical thrombectomy. The primary end-point is 
recanalization on diagnostic catheter angiography assessment prior to mechanical 
thrombectomy.  The lead-in phase testing a novel therapeutic ultrasound device is being 
launched now at 4 US hub-and-spokes systems. 
 
Other new and exciting updates 
Pat Lyden, Dileep Yavagal, Simon de Meyer  
  
Reperfusion of the ischemic territory that occurs too late can also exacerbate tissue damage 
by reperfusion injury. This problem does not only occur after successful thrombolysis but 
also often complicates stroke outcome after successful mechanical thrombectomy. Hence, 
there continues to be a critical need for novel therapies for AIS, including better ways for 
thrombolysis and better ways to guarantee neuroprotection upon recanalization. 
Many previous neuroprotectant failures (promising drugs emerge from pre-clinical 
development only to fail in large stroke patient trials) might be traced to a fundamental 
dogmatic misconception of the mammalian brain. New understanding of the neurovascular 
unit indicates the brain uses at least 7 main categories of cell types: neurons, astrocytes, 
endothelial cells, oligodendroglia, pericytes, ependymal cells and microglia. Recently, 
emerging data suggests the elements of the NVU respond to injury (ischemia, trauma) 
differently, and then respond to treatment differentially. Understanding this differential 
susceptibility to injury—and subsequent differential response to therapy—has led to a 
novel, striking re-interpretation of prior clinical therapeutic trial failures.  
In some patients however, tPA can cause internal bleeding and other complications. 3K3A-
APC, is a pleiotropic cytoprotectant and may reduce thrombolysis associated hemorrhage. 
3K3A-APC’s cytoprotective properties may be useful in protecting ischemic brain tissue 
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from further damage, while reducing the risk of treatment-related bleeding. The 
NeuroNEXT trial NN104 (RHAPSODY) trial established the safety, tolerability and 
activity of 3K3A-APC, following the use of tissue plasminogen activator (tPA) in subjects 
who have experienced moderately severe acute hemispheric ischemic stroke. Results were 
presented at the International Stroke Conference in January, 2018 and confirmed that 
3K3A-APC appears safe and tolerable, and that a suggestion of vasculoprotection (reduced 
hemorrhage) requires confirmation in a larger trial. The next phase of development 
includes further pre-clinical development, hopefully via the new Stroke Pre-clinical 
Assessment Network (SPAN) and further dose finding studies in patients via StrokeNET. 
Together, these development efforts will not only advance one drug to Phase 3 trial, these 
joint efforts among SPAN and StrokeNET will establish the validity of rigorous pre-
clinical development in parallel and in concert with early proof of efficacy in stroke 
patients. The paradigm challenges the dogma “bench-to-bedside-to-bench” in favor of a 
more realistic, collaborative joint development effort in which basic and translational 
scientists work together in real-time.  
 
The natural history of stroke recovery depends on endogenous stems cells in the adult and 
pediatric brain. This recovery is incomplete in most patients and exogenous cell-based 
therapy shows great promise to significantly enhance this stroke recovery. Among different 
cell types, mesenchymal stem cells (MSCs) are most attractive for clinical translation. 
MSCs are adult stem cells that are multipotent, non-hematopoietic stem cells found in the 
stromal fraction of the bone marrow, along with the connective tissue of most organs. They 
are an appealing cell source due to the relative ease in which they can be retrieved, 
developed, and expanded for therapeutic application. Among various routes of cell delivery 
for ischemic stroke, the intra-arterial (IA) route of stem cell transport is most attractive as 
it targets delivery of cells to the ischemic brain bypassing systemic trapping of cells seen 
with intravenous delivery and much less invasive than direct stereotactic or intraventricular 
delivery. Furthermore, IA delivery of cells leads to a wide distribution of cells in the 
ischemic brain as MSCs home in to ischemic tissue via the vasculature using the CXCR4-
SDF-1 signaling pathway. Thus, IA cell delivery leads to a substantial number of MSCs in 
the core and penumbra of the infarct optimizing the trophic mechanism of benefit for stroke 
recovery: anti-inflammation, neuroprotection and stimulation of endogenous stem cells. 
This suggests great potential for clinical translation of IA delivered MSCs for ischemic 
stroke, especially considering the growing clinical application of endovascular treatment 
for AIS.  
 
A major concern for IA delivery of cells is the potential for brain ischemia that could result 
from administered cells compromising blood flow in the microcirculation. Pre-clinical 
work addressing this issue shows that such ischemia depends on the dose of IA delivery 
and can be fully mitigated by lowering cell doses in small and larger animal models. 
Furthermore, the lower (MTD) dose of cells, when given at 24-48 hours after stroke onset 
is efficacious for functional recovery and reduction of infarct volume in rodent stroke 
models. The first randomized trial (Phase 2a) of IA cell therapy in 48 patients, RECOVER-
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Stroke was presented at the European Stroke Conference in 2015 and recently accepted for 
publication. The study showed safety of autologous IA cell delivery in anterior circulation 
ischemic stroke at a median of 18 days from stroke onset with no difference in efficacy. A 
larger phase 2b clinical trial with allogenic MSCs given between 24-36 hours is planned to 
move towards clinical translation of this this promising approach.  
 
Limited data exist on clot composition and detailed characteristics of arterial thrombi 
associated with large vessel occlusion in acute ischemic stroke. Advances in endovascular 
thrombectomy and related imaging modalities have created a unique opportunity to analyze 
thrombi removed from cerebral arteries. Insights into thrombus composition may lead to 
future advancements in acute ischemic stroke treatment and improved clinical outcomes. 
Such detailed information can reveal novel insights and open improved recanalization. 
Some thrombi are particularly rich in von Willebrand factor, leading to the concept of 
developing a novel thrombolytic strategy using the von Willebrand factor-cleaving enzyme 
ADAMTS13. Similarly, the remarkable amount of extracellular DNA (derived from 
neutrophil extracellular traps) had led to using DNase1 as a prothrombolytic drug in 
experimental studies. The testing hypothesis that will be presented is one of using a 
thrombolytic cocktail (tPA + ADAMT13 + DNAse) instead of tPA alone. 
 
Discussion Panel 
Clark Haley, Antoni Davalos, Markku Kaste, Chris Levi   
 
Key Points:  
 
 Existing treatment with thrombolysis and thrombectomy still leave half of patients 
with disability and substantial room for new experimental approaches. 
 
 Ongoing approaches along this line include remote ischemic preconditioning, 
enhancing collaterals through oxygen carriers or sonothrombolysis, targeting the 
multiplicity of vulnerable cell populations in the neurovascular unit, stem cells, and a 
better understanding of clot composition.                
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